



(51) International Patent Classification:

A61K 9/08 (2006.01) A61P 31/00 (2006.01)

A61P 37/06 (2006.01) A61P 37/02 (2006.01)

C07K 14/81 (2006.01) A61K 47/18 (2017.01)

A61K 38/00 (2006.01) A61K 47/36 (2006.01)

(21) International Application Number:

PCT/US2022/016864

(22) International Filing Date:

17 February 2022 (17.02.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2102258.7 17 February 2021 (17.02.2021) GB

(71) Applicant: **ARECOR LIMITED** [GB/GB]; Chesterford Research Park, Little Chesterford, Saffron Walden CB10 1XL (GB).

(72) Inventor; and

(71) Applicant: **AMANULLAH, Ashraf** [US/US]; c/o Inhibrx, Inc., 11025 N. Torrey Pines Road, Suite 200, La Jolla, California 92037 (US).

(72) Inventors: **JEZEK, Jan**; c/o Arecor Limited, Chesterford Research Park, Little Chesterford, Saffron Walden CB10 1XL (GB). **GERRING, David**; c/o Arecor Limited, Chesterford Research Park, Little Chesterford, Saffron Walden CB10 1XL (GB). **CREMIN, Joshua**; c/o Arecor Limited, Chesterford Research Park, Little Chesterford, Saffron Walden CB10 1XL (GB). **PINTO, Jorge**; c/o Arecor Limited, Chesterford Research Park, Little Chesterford, Saffron Walden CB10 1XL (GB). **LOBO, Brian**; c/o Inhibrx, Inc., 11025 N. Torrey Pines Road, Suite 200, La Jolla, California 92037 (US). **HAYES, Bradley**; c/o Inhibrx, Inc., 11025 N. Torrey Pines Road, Suite 200, La Jolla, California 92037 (US).

(74) Agent: **KOZAKIEWICZ, Cynthia A.** et al.; Cooley LLP, 1299 Pennsylvania Ave., Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,

MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

— with sequence listing part of description (Rule 5.2(a))

(54) Title: AQUEOUS SOLUTION COMPOSITIONS FOR INCREASING STABILITY OF ENGINEERED DIMERIC PROTEINS

(57) Abstract: The present application relates to aqueous solution compositions of engineered dimeric proteins comprising monomers that comprise at least one human serpin polypeptide operably linked to a human immunoglobulin Fc polypeptide or a polypeptide that is derived from an immunoglobulin Fc polypeptide, at low buffer concentrations and low ionic strength and containing a neutral amino acid. The aqueous solution compositions increase the stability of the an Fc domain in aqueous solution compositions, and in particular increase the stability of an engineered dimeric protein.

Aqueous solution compositions for increasing stability of engineered dimeric proteins**Related Applications**

[001] This application claims the benefit of Patent Application No. 2102258.7, filed in Great Britain on February 17, 2021, the contents of which are hereby incorporated by reference in their entirety

Incorporation by Reference of Sequence Listing

[002] The contents of the text file named INHI-702_001WO Sequence_Listing.txt which was created on February 16, 2022, and is 148 kilobytes in size, are incorporated herein by reference in their entirety.

Common Ownership Under Joint Research Agreement

[003] The subject matter disclosed in this application was developed, and the claimed invention was made by, or on behalf of, one or more parties to a Joint Research Agreement that was in effect on or before the effective filing date of the claimed invention. The parties to the Joint Research Agreement are as follows: Arecor Limited and Inhibrx, Inc.

Field of Invention

[004] This invention relates to aqueous solution compositions of an engineered dimeric protein comprising an Fc domain at low buffer concentrations and low ionic strength and containing a neutral amino acid.

Background

[005] Engineered proteins comprising an Fc domain are widely used in therapy. The Fc domain is the C-terminal region of an antibody that interacts with cell surface receptors called Fc receptors and some proteins of the complement system and thereby activate the immune system. In IgG, IgA and IgD antibody isotypes, the Fc domain is composed of two identical protein chain fragments, each of which is derived from the second and third constant domains of the antibody's heavy chain. In IgM and IgE antibody isotypes, the Fc domain is composed of two identical protein chain fragments, each of which is derived from the second, third and fourth constant domains of the antibody's heavy chain. The molecular weight of an Fc domain may typically be in the range 25-40 kDa, and may be larger where glycosylation is present. A wide range of physiological effects result from the activation of the immune system mediated by antibody Fc domain binding, including cell lysis and degranulation of mast cells, basophils and eosinophils.

[006] A wide range of engineered antibody proteins have been developed, including bispecific and trispecific antibodies. A number of engineered proteins have also been developed wherein the Fc, separated from the Fab parts of an antibody molecule (the parts that confer antigen binding specificity) can serve a purpose different from its physiological purpose, in particular, the purpose of extending the in vivo half-life of the engineered protein.

WO2013/003641A2 and WO2016/069574A1 (INHIBRX) disclose engineered dimeric proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin.

[007] When formulated as aqueous solutions, proteins can be susceptible to degradation and consequent loss of biological activity while stored. The degradation can be physical in nature, including aggregation, precipitation or gel formation. The degradation can also be chemical in nature, including hydrolytic cleavage, deamidation, cyclic imide formation, aspartate/glutamate isomerization or oxidation.

[008] The rates of the degradation processes increase with increasing temperature, and protein therapeutic molecules are generally more stable at lower temperatures. However, it is often challenging to develop a therapeutic protein product that is stable in liquid form for the duration of the intended shelf-life (typically 24 months), even under refrigeration. In addition, to ensure convenience for patients there is often a need to develop products that are stable at elevated temperatures, such as up to 25 °C or up to 30 °C, either for a specific period of time or for their entire shelf-life.

[009] One of the most critical parameters to control the stability of protein therapeutics is pH. Therefore, pH optimization is a key step in formulation development. Many therapeutic proteins are formulated at a selected pH between 4.0-8.5. It is thought to be important to ensure that the pH is maintained at the selected value and pH fluctuations are minimized. Therefore, it has been understood that a certain degree of buffering capacity is needed in the formulation. Larger protein molecules typically have some self-buffering capacity due to the presence of ionisable groups amongst the amino acid side chains of the polypeptide backbone.

[010] The present invention provides compositions that increase the stability of engineered proteins that comprise an Fc domain in aqueous solution compositions, and in particular increase the stability of an engineered dimeric protein wherein each monomer of the dimeric protein comprises at least one human serpin polypeptide operably linked to a human immunoglobulin Fc polypeptide or a polypeptide that is derived from an immunoglobulin Fc polypeptide ("the engineered dimeric protein of the invention").

Summary of the invention

[011] The present disclosure provides an aqueous solution composition of pH in the range 6.0 to 8.0 comprising: an engineered dimeric protein wherein each monomer of the dimeric protein comprises at least one human serpin polypeptide operably linked to a human immunoglobulin Fc polypeptide or a polypeptide that is derived from an immunoglobulin Fc polypeptide; optionally one or more buffers being substances having at least one ionisable group with a pK_a in the range 4.0 to 10.0 and which pK_a is within 2 pH units of the pH of the composition; a neutral amino acid; and an uncharged tonicity modifier; wherein the buffers are present in the composition at a total concentration of 0-10 mM; and wherein the total ionic strength of the composition excluding the contribution of the engineered dimeric protein is less than 30 mM.

[012] In some embodiments of the aqueous solution composition disclosed herein, the human serpin polypeptide is a human alpha-1 antitrypsin (AAT) polypeptide or is derived from a human AAT polypeptide. In some embodiments of the aqueous solution composition disclosed herein, each monomer of the dimeric protein comprises one human serpin polypeptide. In some embodiments of the aqueous solution composition disclosed herein, the human serpin polypeptide has the sequence of SEQ ID NO: 1 or 2. In some embodiments of the aqueous solution composition disclosed herein, the human immunoglobulin Fc polypeptide or a polypeptide that is derived from an immunoglobulin Fc polypeptide is a modified human IgG4 Fc polypeptide. In some embodiments of the aqueous solution composition disclosed herein, the human immunoglobulin Fc polypeptide or a polypeptide that is derived from an immunoglobulin Fc polypeptide is a modified human IgG4 Fc polypeptide and has the sequence of any one of SEQ ID NOs: 28-43. In some embodiments of the aqueous solution composition disclosed herein, each monomer of the dimeric protein has the sequence of SEQ ID No: 56.

[013] In some embodiments of the aqueous solution composition disclosed herein, the protein is present at a concentration of 1-400 mg/ml e.g., 10-200 mg/ml e.g. 20-100 mg/ml e.g. 30-60 mg/ml e.g. about 35 mg/ml or about 50 mg/ml.

[014] In some embodiments of the aqueous solution composition disclosed herein, buffers are present at a total concentration of 0.1-10 mM, such as 0.5-10 mM such as 1-10 mM, such as 1-8 mM, such as 1-6 mM, such as 2-6 mM, such as 2-5 mM e.g. 3-5 mM. In some embodiments, the aqueous solution composition disclosed herein is substantially free of buffers.

[015] In some embodiments of the aqueous solution composition disclosed herein, the buffer comprises ionisable groups with pK_a within 1 unit of the pH of the composition.

[016] In some embodiments of the aqueous solution composition disclosed herein, the buffer or buffers is/are selected from the group consisting of citrate, histidine, maleate, sulphite, aspartame, aspartate, glutamate, tartrate, adenine, succinate, ascorbate, benzoate, phenylacetate, gallate, cytosine, p-aminobenzoic acid, sorbate, acetate, propionate, alginate, urate, 2-(N-morpholino)ethanesulphonic acid, bicarbonate, bis(2-hydroxyethyl)iminotris(hydroxymethyl)methane, N-(2-acetamido)-2-iminodiacetic acid, 2-[(2-amino-2-oxoethyl)amino]ethanesulphonic acid, piperazine, N,N'-bis(2-ethanesulphonic acid), phosphate, N,N-bis(2-hydroxyethyl)-2-aminoethanesulphonic acid, 3-[N,N-bis(2-hydroxyethyl)amino]-2-hydroxypropanesulphonic acid, triethanolamine, piperazine-N,N'-bis(2-hydroxypropanesulphonic acid), tris(hydroxymethyl)aminomethane (TRIS), N tris(hydroxymethyl)glycine and N-tris(hydroxymethyl)methyl-3-aminopropanesulphonic acid, and salts thereof, and combinations thereof. In some embodiments of the aqueous solution composition disclosed herein, the buffer is selected from the group consisting of citrate, histidine, maleate, tartrate, benzoate, acetate, bicarbonate, phosphate and tris(hydroxymethyl)aminomethane (TRIS), for example, selected from phosphate and TRIS.

[017] In some embodiments of the aqueous solution composition disclosed herein, the uncharged tonicity modifier is selected from the group consisting of polyols, sugars (e.g. monosaccharides and disaccharides) and sugar alcohols. In some embodiments of the aqueous solution composition disclosed herein, the uncharged tonicity modifier is selected from the group consisting of glycerol, 1,2-propanediol, mannitol, sorbitol, glucose, sucrose, trehalose, PEG300 and PEG400, and in particular is selected from glycerol, mannitol, sucrose and trehalose. In some embodiments, the aqueous solution composition disclosed herein comprises a disaccharide as an uncharged tonicity modifier. In some embodiments, the aqueous solution composition disclosed herein comprises sucrose and/or trehalose as the uncharged tonicity modifier, in particular trehalose.

[018] In some embodiments of the aqueous solution composition disclosed herein, the total concentration of the uncharged tonicity modifier, or combination of more than one tonicity modifier, is 50-1000 mM, such as 200-600 mM, 200-500 mM or wherein the total concentration of the uncharged tonicity modifier, or combination of more than one tonicity modifier, is 50-500 mM, such as 100-400 mM, 150-350 mM, 200-300 mM or about 250 mM.

[019] In some embodiments of the aqueous solution composition disclosed herein, the osmolarity of the composition is 200-500 mOsm/L e.g. about 300 mOsm/L or wherein the osmolarity of the composition is 300-500 mOsm/L e.g. about 400-460 mOsm/L.

[020] In some embodiments, the aqueous solution composition disclosed herein comprises a neutral amino acid selected from glycine, methionine, proline, alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, tryptophan, serine, threonine, asparagine and glutamine. In some embodiments, the neutral amino acid is selected from glycine, methionine and proline. In some embodiments, the aqueous solution composition disclosed herein comprises proline as a neutral amino acid. In some embodiments, the aqueous solution composition disclosed herein comprises glycine as a neutral amino acid. In some embodiments, the aqueous solution composition disclosed herein comprises proline and methionine as neutral amino acids. In some embodiments, the aqueous solution composition disclosed herein comprises glycine and methionine as neutral amino acids.

[021] In some embodiments of the aqueous solution composition disclosed herein, the total concentration of the one or more neutral amino acids in the composition is 20 to 600 mM, such as 20 to 500 mM, such as 20 to 400 mM, such as 20 to 300 mM e.g. 50 to 300 mM. In some embodiments of the aqueous solution composition disclosed herein, the total concentration of the one or more neutral amino acids in the composition is 50 to 200 mM, 100 to 200 mM or 100 to 150 mM.

[022] In some embodiments of the aqueous solution composition disclosed herein, the total ionic strength of the composition excluding the contribution of the engineered dimeric protein is less than 20 mM. In some embodiments of the aqueous solution composition disclosed herein, the total ionic strength of the composition excluding the contribution of the engineered dimeric protein is less than 10 mM.

[023] In some embodiments of the aqueous solution composition disclosed herein, the pH is between 6.8 and 7.8, for example between 7.0 and 7.8, between 7.1 and 7.6, between 7.1 and 7.5, between 7.2 and 7.5, between 7.1 and 7.4, between 7.2 and 7.3; or is about 7.2 or about 7.3.

[024] In some embodiments, the aqueous solution composition disclosed herein comprises a non-ionic surfactant. In some embodiments, the non-ionic surfactant is selected from the group consisting of an alkyl glycoside, a polysorbate, an alkyl ether of polyethylene glycol, a block copolymer of polyethylene glycol and polypropylene glycol (poloxamer), and an alkylphenyl ether of polyethylene glycol. In some embodiments, the non-ionic surfactant is a polysorbate such as polysorbate 20 or polysorbate 80. In some embodiments, the non-ionic surfactant is a block copolymer of polyethylene glycol and polypropylene glycol (poloxamer), such as poloxamer 188.

[025] In some embodiments of the aqueous solution composition disclosed herein, the non-ionic surfactant is present at a concentration of 10-2000 µg/ml, such as 50-1000 µg/ml, e.g. 100-500 µg/ml e.g. about 200 µg/ml or wherein the non-ionic surfactant is present at a concentration of 250-1500 µg/ml e.g. 750-1250 µg/ml e.g. about 1000 µg/ml. In some embodiments, the aqueous solution composition disclosed herein comprises a preservative such as a phenolic or benzylic preservative. In some embodiments, the phenolic or benzylic preservative is selected from the group consisting of phenol, m-cresol, chlorocresol, benzyl alcohol, propyl paraben and methyl paraben.

[026] In some embodiments of the aqueous solution composition disclosed herein, the preservative is present at a concentration of 10-100 mM, such as 20-80 mM e.g. 25-50 mM.

[027] In some embodiments, the aqueous solution composition disclosed herein is a composition for use in therapy.

[028] In some embodiments, the aqueous solution composition disclosed herein is a pharmaceutical composition.

[029] The present disclosure also provides a method of treating or alleviating a symptom of a disease or disorder associated with aberrant serine protease expression or activity in a subject in need thereof, the method comprising administering an aqueous solution composition disclosed herein.

[030] The present disclosure also provides a method of treating or alleviating inflammation or a symptom of an inflammatory disease or disorder while reducing the risk of infection, in a subject in need thereof, the method comprising administering to said subject an aqueous solution composition disclosed herein.

[031] The present disclosure also provides a method of reducing the risk of infection in a subject in need thereof, the method comprising administering to said subject an aqueous solution composition disclosed herein.

[032] The present disclosure also provides a method of treating or alleviating a symptom of AAT deficiency in a subject in need thereof, the method comprising administering to said subject an aqueous solution composition of the present disclosure, wherein the human serpin polypeptide is a human alpha-1 antitrypsin (AAT) polypeptide or is derived from a human AAT polypeptide.

[033] Also provided herein, is an aqueous solution composition of the present disclosure, for use in a method of treating or alleviating a symptom of a disease or disorder associated with aberrant serine protease expression or activity in a subject in need thereof.

[034] Also provided herein, is an aqueous solution composition of the present disclosure, for use in a method of treating or alleviating inflammation or a symptom of an inflammatory disease or disorder while reducing the risk of infection, in a subject in need thereof.

[035] Also provided herein, is an aqueous solution composition of the present disclosure, for use in a method of reducing the risk of infection in a subject in need thereof.

[036] Also provided herein is an aqueous solution composition of the present disclosure, for use in a method of treating or alleviating a symptom of AAT deficiency in a subject in need thereof, wherein the human serpin polypeptide is a human alpha- 1 antitrypsin (AAT) polypeptide or is derived from a human AAT polypeptide.

[037] The present disclosure also provides, use of an aqueous solution composition of the present disclosure, for the manufacture of a medicament for treating or alleviating a symptom of a disease or disorder associated with aberrant serine protease expression or activity in a subject in need thereof.

[038] The present disclosure also provides, use of an aqueous solution composition of the present disclosure, for the manufacture of a medicament for treating or alleviating inflammation or a symptom of an inflammatory disease or disorder while reducing the risk of infection, in a subject in need thereof.

[039] The present disclosure also provides, use of an aqueous solution composition of the present disclosure, for the manufacture of a medicament for reducing the risk of infection in a subject in need thereof.

[040] The present disclosure also provides, use of an aqueous solution composition of the present disclosure, for the manufacture of a medicament for treating or alleviating a symptom of AAT deficiency in a subject in need thereof, wherein the human serpin polypeptide is a human alpha- 1 antitrypsin (AAT) polypeptide or is derived from a human AAT polypeptide.

[041] In some embodiments of the aqueous solution composition of the present disclosure for use, or use, according to any of the methods of the present disclosure, the inflammatory disease or disorder is selected from the following: alpha- 1 antitrypsin (AAT) deficiency, alpha- 1 antitrypsin (AAT) deficiency, emphysema, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), allergic asthma, cystic fibrosis, cancers of the lung, ischemia-reperfusion injury, ischemia/reperfusion injury following cardiac transplantation, myocardial infarction, rheumatoid arthritis, septic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, type I and/or type II diabetes, pneumonia, sepsis, graft versus host disease (GVHD), wound healing, systemic lupus erythematosus, and multiple sclerosis.

[042] In some embodiments of the aqueous solution composition of the present disclosure for use, or use, according to any of the methods of the present disclosure, the infection is selected from bacterial infections, fungal infections and viral infections.

[043] In some embodiments of the aqueous solution composition of the present disclosure for use, or use, according to any of the methods of the present disclosure, the subject is a human.

[044] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are expressly incorporated by reference in their entirety. In cases of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples described herein are illustrative only and are not intended to be limiting.

[045] Other features and advantages of the invention will be apparent from and encompassed by the following detailed description and claims.

Detailed description of the invention

[046] Described herein are stable aqueous solution compositions of the engineered dimeric protein of the invention having absent or a low concentration of buffer and low ionic strength.

[047] It should be noted that all references herein to "pH" refer to the pH of a composition evaluated at 25 °C. All references to "pK_a" refer to the pK_a of an ionisable group evaluated at 25 °C (see CRC Handbook of Chemistry and Physics, 79th Edition, 1998, D. R. Lide). If required, pK_a values of amino acid side chains as they exist in a polypeptide can be estimated using a suitable calculator.

[048] The present inventors believe that buffers have a detrimental impact on the engineered dimeric protein of the invention. Therefore, the concentration of buffer in the composition should be limited as much as possible.

[049] The buffer(s) where present will have buffering capacity at the pH of the composition. Buffers typically comprise ionisable groups with pK_a within 1 pH unit of the pH of the composition, however, a moiety which has ionisable groups with pK_a 1 pH unit greater or less than the pH of the composition may also provide some buffering effect if present in a sufficient amount. In one embodiment, the (or a) buffer comprises ionisable groups with pK_a within 1 pH unit of the pH of the composition. In another embodiment, the (or a) buffer comprises ionisable groups with pK_a within 1.5 pH units of the pH of the composition (such as between 1 and 1.5 pH units of the pH of the composition). In a further embodiment, the (or a) buffer comprises ionisable groups with pK_a within 2 pH units of the pH of the composition (such as between 1.5 and 2 pH units of the pH of the composition).

[050] In an embodiment, the composition is substantially free of buffers. As used herein, "substantially free" means the aqueous solution composition contains less than 0.1 mM of buffers e.g. does not contain any buffers. More preferably, a small amount of buffer is present in order to avoid or limit pH fluctuation which is not desirable. In an embodiment, the composition contains a single buffer. In an embodiment, the composition contains two buffers. Suitably, one or more buffers are present.

[051] The total concentration of buffers in the composition is 0-10 mM. In one embodiment, the total concentration of buffers in the composition is 9.5 mM or less, such as 9 mM or less, such as 8 mM or less, such as 7 mM or less, such as 6 mM or less, such as 5.5 mM or less, such as 5 mM or less, such as 4.5 mM or less, such as 4 mM or less, such as 3 mM or less, such as 2 mM or less, such as 1 mM or less, such as 0.5 mM or less, such as 0.4 mM or less, such as 0.3 mM or less, such as 0.2 mM or less. In one embodiment, the total concentration of buffers is 0.1 mM or more, such as 0.2 mM or more, such as 0.3 mM or more, such as 0.4 mM or more, such as 0.5 mM or more, such as 1 mM or more. Suitably the total concentration of buffers is 0.1-10 mM, such as 0.5-10 mM, such as 1-10 mM, such as 1-8 mM, such as 1-6 mM, such as 2-6 mM, such as 2-5 mM, e.g. 3-5 mM.

[052] When considering the concentration of buffer in solution, any buffering capacity of the engineered dimeric protein of the invention itself should be excluded.

[053] The pH of an aqueous solution decreases if an acid is added and increases if a base is added. At a given temperature and atmospheric pressure, the magnitude of the pH decrease on addition of an acid or the magnitude of the pH increase on addition of a base depends on (1) the amount of the acid or the base added, (2) the starting pH of the aqueous solution (i.e. prior to the addition of the acid or the base) and (3) the presence of a buffer. Thus, (1) starting from a given pH, the addition of a greater amount of an acid or a base will result in greater magnitude of pH change, (2) addition of a given amount of an acid or a base will result in the greatest pH change at neutral pH (i.e. pH 7.0) and the magnitude of the pH change will decrease as the starting pH moves away from pH 7.0 and (3) the magnitude of the pH change, starting from a given pH, will be smaller in the presence of a buffer than in the absence of a buffer. A buffer thus has the ability to reduce the change in pH if an acid or a base is added to the solution.

[054] Suitably, a substance is considered to be a buffer if it is capable of reducing the magnitude of the pH change of a solution to 75%, preferably 50%, most preferably to 25%, compared with an identical solution that does not comprise the buffer, when either strong acid or a strong base is added resulting in 0.1 mM increase of the acid or the base in the solution.

[055] Conversely, suitably, a substance is not considered to be a buffer if it is not capable of reducing the magnitude of the pH change of a solution to 75%, preferably 50%, most

preferably to 25%, compared with an identical solution that does not comprise the substance, when either strong acid or a strong base is added resulting in 0.1 mM increase of the acid or the base in the solution.

[056] In one embodiment, the or a buffer is an amino acid. In another embodiment, the or a buffer is not an amino acid. In an embodiment the composition is free of the amino acids lysine, arginine, histidine, glutamate and aspartate. In an embodiment the composition is free of cysteine.

[057] Where present, suitable buffers include, but are not limited to: citrate, histidine, maleate, sulphite, aspartame, aspartate, glutamate, tartrate, adenine, succinate, ascorbate, benzoate, phenylacetate, gallate, cytosine, *p*-aminobenzoic acid, sorbate, acetate, propionate, alginate, urate, 2-(*N*-morpholino)ethanesulphonic acid, bicarbonate, bis(2-hydroxyethyl) iminotris(hydroxymethyl)methane, *N*-(2-acetamido)-2-iminodiacetic acid, 2-[(2-amino-2-oxoethyl)amino]ethanesulphonic acid, piperazine, *N,N'*-bis(2-ethanesulphonic acid), phosphate, *N,N*-bis(2-hydroxyethyl)-2-aminoethanesulphonic acid, 3-[*N,N*-bis(2-hydroxyethyl)amino]-2-hydroxypropanesulphonic acid, triethanolamine, piperazine-*N,N'*-bis(2-hydroxypropanesulphonic acid), tris(hydroxymethyl)aminomethane (TRIS), *N*-tris(hydroxymethyl)glycine and *N*-tris(hydroxymethyl)methyl-3-aminopropanesulphonic acid, and salts thereof, and combinations thereof.

[058] In one embodiment, the buffer is selected from the group consisting of citrate, histidine, maleate, tartrate, benzoate, acetate, bicarbonate, phosphate and TRIS e.g. is selected from the group consisting of histidine, maleate, tartrate, benzoate, acetate, bicarbonate, phosphate and TRIS e.g. is selected from the group consisting of histidine, acetate, phosphate and TRIS.

[059] In one embodiment, the buffer is phosphate (e.g. sodium phosphate) or TRIS. In one embodiment, the buffer is phosphate (e.g. sodium phosphate). Suitably the buffer is TRIS.

[060] In an embodiment, the composition does not comprise sodium phosphate.

[061] The principal solvent for compositions of the invention is water, such as water for injection. Other components of the compositions (e.g. a polyol) may contribute to solubilisation of the engineered dimeric protein.

[062] The composition comprises an uncharged tonicity modifier, such as a polyol, a sugar e.g. a monosaccharide or disaccharide, or a sugar alcohol. In one embodiment, the composition comprises a tonicity modifier selected from the group consisting of glycerol, 1,2-propanediol, mannitol, sorbitol, glucose, sucrose, trehalose, PEG300 and PEG400 e.g. selected from the group consisting of glycerol, 1,2-propanediol, mannitol, sorbitol, sucrose, trehalose, PEG300 and PEG400. Mixtures of uncharged tonicity modifiers such as trehalose and sucrose, or trehalose and mannitol are contemplated. In one embodiment, the uncharged tonicity modifier is selected from glycerol, mannitol, sucrose and trehalose. Suitably the

uncharged tonicity modifier is a disaccharide. Thus, in another embodiment, the uncharged tonicity modifier is sucrose and/or trehalose, and in particular is trehalose. When included, an uncharged tonicity modifier (or combination of more than one tonicity modifier) is typically employed in the composition at a total concentration of 50-1000 mM, for example 200-600 mM, such as about 200-500 mM. In one embodiment, the total concentration of uncharged tonicity modifier (or combination of more than one tonicity modifier) is 50-500 mM, such as 100-400 mM, 150-350 mM, 200-300 mM or about 250 mM. Another concentration of interest is about 150 mM.

[063] In an embodiment, when trehalose is the uncharged tonicity modifier, whether alone or in combination with one or more other uncharged tonicity modifiers, the concentration of trehalose in the composition is 50-180 mM e.g., 50-150 mM.

[064] The composition suitably has an osmolarity which is physiologically acceptable and thus suitable for parenteral administration. Thus, the osmolarity of the composition is suitably 200-500 mOsm/L e.g., about 300 mOsm/L. The composition is, for example, isotonic with human plasma. In another embodiment, the osmolarity of the composition is 300-500 mOsm/L e.g. about 400-460 mOsm/L. Compositions may also be hypotonic, or hypertonic, e.g. those intended for dilution prior to administration.

[065] The composition comprises a neutral amino acid. As used herein, a neutral amino acid is an amino acid the side chain of which does not contain an ionisable group which is significantly ionized (e.g. more than 20% especially more than 50% of the side chain have a minus or plus charge) at the pH of the composition. Example neutral amino acids are glycine, methionine, proline, alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, tryptophan, serine, threonine, asparagine and glutamine and in particular the L isomers thereof.

[066] In one embodiment, the composition comprises a neutral amino acid selected from the group consisting of glycine, methionine and proline. In one embodiment, the composition comprises proline as neutral amino acid. In one embodiment, the composition comprises glycine as neutral amino acid. Mixtures of neutral amino acids are contemplated. In one embodiment, the composition comprises proline and methionine as neutral amino acids. In one embodiment, the composition comprises glycine and methionine as neutral amino acids. As can be seen from the examples, the presence of a neutral amino acid was found to enhance the stability of the composition.

[067] In one embodiment, the concentration of the neutral amino acid, for example, proline or glycine, is 20 to 600 mM, such as 20 to 500 mM, such as 20 to 400 mM, such as 20 to 300 mM or 50 to 300 mM. In one embodiment, the concentration of the neutral amino acid, for example, proline or glycine, is 50 to 200 mM, 100 to 200 mM or 100 to 150 mM.

[068] In one embodiment, methionine as a neutral amino acid, when present in the

composition, is present at a concentration of 2 to 10 mM, e.g. about 2 mM.

[069] In one embodiment, the concentration of all the neutral amino acids (i.e. the total concentration) in the composition, for example, proline or glycine and methionine, is 20 to 600 mM, such as 20 to 500 mM, such as 20 to 400 mM, such as 20 to 300 mM or 50 to 300 mM. In one embodiment, the concentration of all the neutral amino acids in the composition, for example, proline or glycine and methionine, is 50 to 200 mM, 100 to 200 mM or 100 to 150 mM.

[070] The composition may comprise a non-ionic surfactant. The non-ionic surfactant may for example be selected from the group consisting of a polysorbate, an alkyl glycoside, an alkyl ether of polyethylene glycol, a block copolymer of polyethylene glycol and polypropylene glycol, and an alkylphenyl ether of polyethylene glycol.

[071] A particularly suitable class of non-ionic surfactants is the polysorbates (fatty acid esters of ethoxylated sorbitan), such as polysorbate 20 or polysorbate 80. Polysorbate 20 is a mono ester formed from lauric acid and polyoxyethylene (20) sorbitan in which the number 20 indicates the number of oxyethylene groups in the molecule. Polysorbate 80 is a mono ester formed from oleic acid and polyoxyethylene (20) sorbitan in which the number 20 indicates the number of oxyethylene groups in the molecule. Polysorbate 20 is known under a range of brand names including in particular Tween 20, and also Alkest TW 20. Polysorbate 80 is known under a range of brand names including in particular Tween 80, and also Alkest TW 80. Other suitable polysorbates include polysorbate 40 and polysorbate 60.

[072] Another suitable class of non-ionic surfactants is the alkyl glycosides, especially dodecyl maltoside. Other alkyl glycosides include dodecyl glucoside, octyl glucoside, octyl maltoside, decyl glucoside, decyl maltoside, tridecyl glucoside, tridecyl maltoside, tetradecyl glucoside, tetradecyl maltoside, hexadecyl glucoside, hexadecyl maltoside, sucrose monooctanoate, sucrose mono decanoate, sucrose monododecanoate, sucrose monotridecanoate, sucrose monotetradecanoate and sucrose monohexadecanoate.

[073] Another suitable class of non-ionic surfactants is alkyl ethers of polyethylene glycol, especially those known under a brand name Brij, such as selected from polyethylene glycol (2) hexadecyl ether (Brij 52), polyethylene glycol (2) oleyl ether (Brij 93) and polyethylene glycol (2) dodecyl ether (Brij L4). Other suitable Brij surfactants include polyethylene glycol (4) lauryl ether (Brij 30), polyethylene glycol (10) lauryl ether (Brij 35), polyethylene glycol (20) hexadecyl ether (Brij 58) and polyethylene glycol (10) stearyl ether (Brij 78).

[074] Another suitable class of non-ionic surfactants is block copolymers of polyethylene glycol and polypropylene glycol, also known as poloxamers, especially poloxamer 188, poloxamer 407, poloxamer 171 and poloxamer 185. Poloxamers are also known under brand names Pluronics or Koliphors. For example, poloxamer 188 is marketed as Pluronic F-68.

[075] Another suitable class of non-ionic surfactants are alkylphenyl ethers of polyethylene glycol, especially 4-(1,1,3,3-tetramethylbutyl)phenyl-polyethylene glycol, also known under a brand name Triton X-100.

[076] In one embodiment, the non-ionic surfactant is a polysorbate or a poloxamer. In one embodiment, the non-ionic surfactant is a polysorbate, such as polysorbate 80 or polysorbate 20. In one embodiment, the non-ionic surfactant is a poloxamer, such as poloxamer 188. The concentration of the non-ionic surfactant in the composition will typically be in the range 10-2000 µg/ml. Exemplary concentrations e.g. for polysorbate surfactants are 50-1000 µg/ml, e.g. 100-500 µg/ml e.g. about 200 µg/ml. Exemplary concentrations e.g. for poloxamer surfactants are 250-1500 µg/ml, e.g. 750-1250 µg/ml e.g. about 1000 µg/ml.

[077] In some embodiments, the poloxamer surfactants concentration are 0.025%-0.15% by weight per volume (w/v) of the composition, e.g. 0.075% to 0.125% by weight per volume (w/v) of the composition, e.g. about 0.1% by weight per volume (w/v) of the composition.

[078] The compositions of the invention may additionally comprise a preservative such as a phenolic or a benzylic preservative. The preservative is suitably selected from the group consisting of phenol, m-cresol, chlorocresol, benzyl alcohol, propyl paraben and methyl paraben, in particular phenol, m-cresol and benzyl alcohol. The concentration of preservative is typically 10-100 mM, for example 20-80 mM, such as 25-50 mM. The optimal concentration of the preservative in the composition is selected to ensure the composition passes the Pharmacopoeia Antimicrobial Effectiveness Test (USP <51>, Vol. 32).

[079] The present inventors believe that the presence of ions has a detrimental impact on the stability of the engineered dimeric protein of the invention. Therefore, the ionic strength of the composition should be limited as much as possible.

[080] The total ionic strength of the composition excluding the contribution of the engineered dimeric protein of the invention is less than 30 mM, suitably less than 25 mM, suitably less than 20 mM, suitably less than 15 mM, suitably less than 10 mM e.g. less than 5 mM. The term "total ionic strength" is used herein as the following function of the concentration of all ions in a solution:

$$I = \sum_{x=1}^n c_x z_x^2 / 2$$

where c_x is molar concentration of ion x (mol L⁻¹), z_x is the net charge of ion c_x . The sum covers all ions (n) present in the solution excluding the contribution of the engineered dimeric protein of the invention. It will be understood that optional neutral amino acids have a net charge of zero in the compositions of the invention and do not thus contribute to the total ionic strength. In any event, the contribution of any neutral amino acids is not included.

[081] The pH of the composition is between 6.0 and 8.0, such as between 6.8 and 7.8, for example between 7.0 and 7.8, between 7.1 and 7.6, between 7.1 and 7.5, between 7.2 and 7.5, between 7.1 and 7.4, between 7.2 and 7.3; or is about 7.2 or about 7.3.

[082] In certain embodiments, the engineered dimeric protein of the invention is substantially pure, that is, the composition comprises a single protein and no substantial amount of any additional protein. In preferred embodiments, the engineered dimeric protein of the invention comprises at least 99%, preferably at least 99.5% and more preferably at least about 99.9% of the total protein content of the composition. In preferred embodiments the engineered dimeric protein of the invention is sufficiently pure for use in a pharmaceutical composition.

[083] The engineered dimeric protein of the invention is suitably present in the composition at a concentration of about 1-400 mg/ml, suitably 10-200 mg/ml, more suitably 20-100 mg/ml e.g. 30-60 mg/ml e.g. about 35 mg/ml or about 50 mg/ml.

[084] In one embodiment, the invention provides an aqueous solution composition of pH in the range 6.8 to 7.8 e.g. 7.0 to 7.8 e.g. 7.1 to 7.6 e.g. 7.1 to 7.5 e.g. about 7.2 or about 7.3 comprising: an engineered dimeric protein wherein each monomer of the dimeric protein comprises at least one human serpin polypeptide operably linked to a human immunoglobulin Fc polypeptide or a polypeptide that is derived from an immunoglobulin Fc polypeptide; a buffer selected from phosphate (e.g. sodium phosphate) or TRIS, e.g. TRIS; a neutral amino acid selected from the group consisting of glycine, methionine and proline e.g. glycine and methionine or proline and methionine; and an uncharged tonicity modifier e.g. a disaccharide e.g. trehalose, sucrose or a mixture of trehalose and sucrose; a non-ionic surfactant selected from a polysorbate and a poloxamer e.g. a poloxamer such as poloxamer 188; wherein buffers are present in the composition at a total concentration of 1-8 mM e.g. 2-6 mM; and wherein the total ionic strength of the composition excluding the contribution of the engineered dimeric protein is less than 20 mM e.g. less than 10 mM e.g. less than 5 mM.

[085] Suitably, the composition of the invention remains as a clear solution following storage at 2-8 °C for extended period of time, such as at least 4 weeks, 8 weeks, 12 weeks, 12 months, 18 months or 24 months.

[086] Suitably, the composition of the invention remains as a clear solution following storage at 25 °C for extended period of time, such as at least 4 weeks, 8 weeks, 12 weeks, 12 months, 18 months or 24 months.

[087] Suitably, the composition of the invention remains as a clear solution following storage at 30 °C for extended period of time, such as at least 4 weeks, 8 weeks, 12 weeks, 12 months, 18 months or 24 months.

[088] Suitably, the composition of the invention remains as a clear solution following storage at 40 °C (i.e. temperature suitable for accelerated stability trials) for a period of time, such as

at least 1 day, 3 days, 1 week, 2 weeks or 4 weeks.

[089] Suitably, the composition of the invention has increased storage stability either at 2-8 °C or at increased temperature as compared to an equivalent composition that comprises higher concentration of the same buffer or buffers.

[090] Suitably, the composition of the invention has increased storage stability either at 2-8 °C or at increased temperature as compared to an equivalent composition that has a higher total ionic strength.

[091] In one embodiment, the composition of the invention comprises no more than 8% high molecular weight species, such as no more than 7%, such as no more than 6%, such as no more than 5%, such as no more than 2%, such as no more than 1%, such as no more than 0.5%, such as no more than 0.3% high molecular weight species (by total weight of the engineered dimeric protein of the invention in the composition, as measured by size-exclusion chromatography or a similar suitable technique) following storage at 2-8 °C for at least 4 weeks, 8 weeks, 12 weeks, 12 months, 18 months or 24 months.

[092] In one embodiment, the composition of the invention comprises no more than 18% high molecular weight species, such as no more than 17%, such as no more than 16%, such as no more than 15%, such as no more than 10%, such as no more than 8%, such as no more than 5%, such as no more than 4%, such as no more than 3%, such as no more than 1% high molecular weight species (by total weight of the engineered dimeric protein of the invention in the composition, as measured by size-exclusion chromatography or a similar suitable technique) following storage at 25 °C for at least 4 weeks, 8 weeks, 12 weeks, 12 months, 18 months or 24 months.

[093] In one embodiment, the composition of the invention comprises no more than 25% high molecular weight species, such as no more than 20%, such as no more than 18%, such as no more than 17%, such as no more than 16%, such as no more than 15%, such as no more than 10%, such as no more than 8%, such as no more than 5%, such as no more than 4%, such as no more than 3%, such as no more than 1% high molecular weight species (by total weight of the engineered dimeric protein of the invention in the composition, as measured by size-exclusion chromatography or a similar suitable technique) following storage at 30 °C for at least 4 weeks.

[094] In one embodiment, the composition of the invention comprises no more than 30% high molecular weight species, such as no more than 25%, such as no more than 20%, such as no more than 18%, such as no more than 17%, such as no more than 16%, such as no more than 15%, no more than 10%, such as no more than 8%, such as no more than 6%, such as no more than 4% high molecular weight species (by total weight of the engineered dimeric protein of the invention in the composition, as measured by size-exclusion

chromatography or a similar suitable technique) following storage at 40 °C for at least 1 day, 3 days, 1 week, 2 weeks or 4 weeks.

[095] As used herein, high molecular weight species are species that result from protein aggregation with an apparent molecular weight greater than the dimeric protein.

[096] In an embodiment, the composition of the invention is a composition for use in therapy. In an embodiment, the composition of the invention is a pharmaceutical composition.

[097] In one embodiment is provided a method of inhibiting or downregulating aberrant serine protease expression or activity in a subject in need thereof, the method comprising administering to said subject an aqueous solution composition as described herein. In some embodiments, the aberrant serine protease expression or activity is associated with an inflammatory disease or disorder or a risk of infection. In some embodiments, the inflammatory disease or disorder is selected from the following: alpha- 1 antitrypsin (AAT) deficiency, emphysema, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), allergic asthma, cystic fibrosis, cancers of the lung, ischemia-reperfusion injury, ischemia/reperfusion injury following cardiac transplantation, myocardial infarction, rheumatoid arthritis, septic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, type I and/or type II diabetes, pneumonia, sepsis, graft versus host disease (GVHD), wound healing, systemic lupus erythematosus, and multiple sclerosis.

[098] In one embodiment, the risk of infection is risk of an infection selected from bacterial infections, fungal infections and viral infections.

[099] In one embodiment is provided a method of treating or alleviating a symptom of a disease or disorder associated with aberrant serine protease expression or activity in a subject in need thereof, the method comprising administering to said subject an aqueous solution composition as described herein. In another embodiment is provided a method of treating or alleviating inflammation or a symptom of an inflammatory disease or disorder while reducing the risk of infection, in a subject in need thereof, the method comprising administering to said subject an aqueous solution composition as described herein. In another embodiment is provided a method of reducing the risk of infection in a subject in need thereof, the method comprising administering to said subject an aqueous solution composition as described herein.

[100] In an embodiment, when the human serpin polypeptide is a human alpha- 1 antitrypsin (AAT) polypeptide or is derived from a human AAT polypeptide, there is provided a method of treating or alleviating a symptom of AAT deficiency in a subject in need thereof, the method comprising administering to said subject an aqueous solution composition as described herein.

[101] In one embodiment is provided an aqueous solution composition as described herein,

for use in a method of treating or alleviating a symptom of a disease or disorder associated with aberrant serine protease expression or activity in a subject in need thereof. In another embodiment is provided an aqueous solution composition as described herein, for use in a method of treating or alleviating inflammation or a symptom of an inflammatory disease or disorder while reducing the risk of infection, in a subject in need thereof. In another embodiment is provided an aqueous solution composition as described herein, for use in a method of reducing the risk of infection in a subject in need thereof.

[102] In an embodiment, when the human serpin polypeptide is a human alpha- 1 antitrypsin (AAT) polypeptide or is derived from a human AAT polypeptide, there is provided an aqueous solution composition as described herein for use in a method of treating or alleviating a symptom of AAT deficiency in a subject in need thereof.

[103] In one embodiment is provided the use of an aqueous solution composition as described herein, for the manufacture of a medicament for treating or alleviating a symptom of a disease or disorder associated with aberrant serine protease expression or activity in a subject in need thereof. In another embodiment is provided the use of an aqueous solution composition as described herein, for the manufacture of a medicament for treating or alleviating inflammation or a symptom of an inflammatory disease or disorder while reducing the risk of infection, in a subject in need thereof. In another embodiment is provided the use of an aqueous solution composition as described herein, for the manufacture of a medicament for reducing the risk of infection in a subject in need thereof.

[104] In an embodiment, when the human serpin polypeptide is a human alpha- 1 antitrypsin (AAT) polypeptide or is derived from a human AAT polypeptide, there is provided use of an aqueous solution composition as described herein for the manufacture of a medicament for treating or alleviating a symptom of AAT deficiency in a subject in need thereof.

[105] Suitably, the subject is a human.

[106] Suitably, the inflammatory disease or disorder is selected from the following: alpha- 1 antitrypsin (AAT) deficiency, emphysema, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), allergic asthma, cystic fibrosis, cancers of the lung, ischemia-reperfusion injury, ischemia/reperfusion injury following cardiac transplantation, myocardial infarction, rheumatoid arthritis, septic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, type I and/or type II diabetes, pneumonia, sepsis, graft versus host disease (GVHD), wound healing, systemic lupus erythematosus, and multiple sclerosis.

[107] Suitably, the infection is selected from bacterial infections, fungal infections and viral infections.

[108] Compositions e.g. those intended for intravenous administration may be prepared as

concentrates for dilution prior to administration.

[109] All embodiments described above with respect to the aqueous solution composition apply equally to methods and uses of the invention.

[110] There is also provided a container, for example made of plastics or glass, containing one dose or a plurality of doses of the composition as described herein. The container can be for example, a vial, a pre-filled syringe, a pre-filled infusion bag, or a cartridge designed to be a replaceable item for use with an injection device.

[111] The compositions of the invention may suitably be packaged for infusion or injection, especially intravenous infusion, intravenous injection, subcutaneous injection or intramuscular injection.

[112] The compositions of the invention may suitably be packed in a vial as a concentrate for intravenous infusion. Prior to use, the concentrate is removed from the vial and diluted into an infusion bag containing a suitable diluent such as saline solution, dextrose solution or water for injection. The diluted composition is subsequently administered by intravenous infusion at a specified infusion rate (e.g., 8-16 mL/min).

[113] An aspect of the invention is an injection or infusion device, particularly a device adapted for subcutaneous or intramuscular injection or infusion, for single or multiple use comprising a container containing one dose or a plurality of doses of the composition of the invention together with an injection needle. In an embodiment, the container is a replaceable cartridge which contains a plurality of doses. In one embodiment, the injection device is in the form of a pen. In one embodiment, the injection device is in the form of a pre-filled syringe. In one embodiment, the injection or infusion device is in the form of a pump or another wearable injection or infusion device.

[114] Compositions according to the invention are expected to have good physical and chemical stability as described herein.

[115] **Description of the sequence listing**

[116] SEQ ID NO: 1 is a full-length human AAT polypeptide sequence.

[117] SEQ ID NO: 2 is a full-length human AAT polypeptide sequence.

[118] SEQ ID NO: 3 is a reactive site loop portion of the AAT protein.

[119] SEQ ID NO: 4 is a reactive site loop portion of the AAT protein.

[120] SEQ ID NO: 5 is a reactive site loop portion of the AAT protein.

[121] SEQ ID NO: 6 is a human IgG1 Fc polypeptide sequence.

[122] SEQ ID NO: 7 is a human IgG1 Fc polypeptide sequence including a hinge region at the N-terminus.

[123] SEQ ID NO: 8 is a modified IgG1 Fc polypeptide sequence with mutations at residues M252, T256 and M428.

[124] SEQ ID NO: 9 is a modified IgG1 Fc polypeptide sequence including a hinge region at the N-terminus, with mutations at residues M252, T256 and M428.

[125] SEQ ID NO: 10 is a modified IgG1 Fc polypeptide sequence where residue G236 is deleted.

[126] SEQ ID NO: 11 is a modified IgG1 Fc polypeptide sequence including a hinge region at the N-terminus, where residue G236 is deleted.

[127] SEQ ID NO: 12 is a modified IgG1 Fc polypeptide sequence with mutations at residues L234 and L235.

[128] SEQ ID NO: 13 is a modified IgG1 Fc polypeptide sequence including a hinge region at the N-terminus, with mutations at residues L234 and L235.

[129] SEQ ID NO: 14 is a modified IgG1 Fc polypeptide sequence with a deletion at residue G236 and mutations at residues L234 and L235.

[130] SEQ ID NO: 15 is a modified IgG1 Fc polypeptide sequence including a hinge region at the N-terminus, with a deletion at residue G236 and mutations at residues L234 and L235.

[131] SEQ ID NO: 16 is a modified IgG1 Fc polypeptide sequence with a deletion at residue G236 and mutations at residues L234, L235, M252, T256, and M428.

[132] SEQ ID NO: 17 is a modified IgG1 Fc polypeptide sequence including a hinge region at the N-terminus, with a deletion at residue G236 and mutations at residues L234, L235, M252, T256, and M428.

[133] SEQ ID NO: 18 is a human IgG2 Fc polypeptide sequence.

[134] SEQ ID NO: 19 is a modified IgG2 Fc polypeptide sequence with a deletion at residue G236 and mutations at residues M252, T256, and M428.

[135] SEQ ID NO: 20 is a human IgG3 Fc polypeptide sequence.

[136] SEQ ID NO: 21 is a modified IgG3 Fc polypeptide sequence with mutations at residues M252, T256, and M428.

[137] SEQ ID NO: 22 is a modified IgG3 Fc polypeptide sequence with a deletion at residue G236.

[138] SEQ ID NO: 23 is a modified IgG3 Fc polypeptide sequence with mutations at residues L234 and L235.

[139] SEQ ID NO: 24 is a modified IgG3 Fc polypeptide sequence with a deletion at residue G236 and mutations at residues L234 and L235.

[140] SEQ ID NO: 25 is a modified IgG3 Fc polypeptide sequence with a deletion at residue G236 and mutations at residues L234, L235, M252, T256, and M428.

[141] SEQ ID NO: 26 is a human IgG4 Fc polypeptide sequence.

[142] SEQ ID NO: 27 is a human IgG4 Fc polypeptide sequence including a hinge region at the N-terminus.

[143] SEQ ID NO: 28 is a modified IgG4 Fc polypeptide sequence with mutations at residues M252, T256 and M428.

[144] SEQ ID NO: 29 is a modified IgG4 Fc polypeptide sequence including a hinge region at the N-terminus, with mutations at residues M252, T256 and M428.

[145] SEQ ID NO: 30 is a modified IgG4 Fc polypeptide sequence with a deletion at residue G236.

[146] SEQ ID NO: 31 is a modified IgG4 Fc polypeptide sequence including a hinge region at the N-terminus, with a deletion at residue G236.

[147] SEQ ID NO: 32 is a modified IgG4 Fc polypeptide sequence with a mutation at residue L235.

[148] SEQ ID NO: 33 is a modified IgG4 Fc polypeptide sequence including a hinge region at the N-terminus, with a mutation at residue L235.

[149] SEQ ID NO: 34 is a modified IgG4 Fc polypeptide sequence with mutations at residues L234 and L235.

[150] SEQ ID NO: 35 is a modified IgG4 Fc polypeptide sequence including a hinge region at the N-terminus, with mutations at residues L234 and L235.

[151] SEQ ID NO: 36 is a modified IgG4 Fc polypeptide sequence with a mutation at residue S228.

[152] SEQ ID NO: 37 is a modified IgG4 Fc polypeptide sequence including a hinge region at the N-terminus, with mutations at residues S228 and L235.

[153] SEQ ID NO: 38 is a modified IgG4 Fc polypeptide sequence including a hinge region at the N-terminus, with mutations at residues S228, L235 and M252.

- [001] SEQ ID NO: 39 is a modified IgG4 Fc polypeptide sequence including a hinge region at the N-terminus, with mutations at residues S228, L235 and M428.
- [002] SEQ ID NO: 40 is a modified IgG4 Fc polypeptide sequence including a hinge region at the N-terminus, with mutations at residues S228, L235, M252 and M428.
- [003] SEQ ID NO: 41 is a modified IgG4 Fc polypeptide sequence with mutations at residues L235, M252, T256 and M428.
- [004] SEQ ID NO: 42 is a modified IgG4 Fc polypeptide sequence including a hinge region at the N-terminus, with mutations at residues L235, M252, T256 and M428.
- [005] SEQ ID NO: 43 is a modified IgG4 Fc polypeptide sequence including a hinge region at the N-terminus, with mutations at residues S228, L235, M252, T256 and M428.
- [006] SEQ ID NO: 44 is a human IgM Fc polypeptide.
- [007] SEQ ID NO: 45 is an AAT polypeptide – IgG-Fc polypeptide fusion protein comprising SEQ ID NO: 1 and SEQ ID NO: 6.
- [008] SEQ ID NO: 46 is an AAT polypeptide – IgG-Fc polypeptide fusion protein comprising SEQ ID NO: 1 and SEQ ID NO: 18.
- [009] SEQ ID NO: 47 is an AAT polypeptide – IgG-Fc polypeptide fusion protein comprising SEQ ID NO: 48 and SEQ ID NO: 6.
- [010] SEQ ID NO: 48 is an AAT polypeptide.
- [011] SEQ ID NO: 49 is an AAT polypeptide – IgG-Fc polypeptide fusion protein comprising SEQ ID NO: 48 and SEQ ID NO: 18.
- [012] SEQ ID NO: 50 is an AAT polypeptide – IgG-Fc polypeptide fusion protein comprising SEQ ID NO: 51 and SEQ ID NO: 18.
- [013] SEQ ID NO: 51 is an AAT polypeptide.
- [014] SEQ ID NO: 52 is an AAT polypeptide – IgG-Fc polypeptide fusion protein comprising SEQ ID NO: 1 and SEQ ID NO: 6.
- [015] SEQ ID NO: 53 is an AAT polypeptide – IgG-Fc polypeptide fusion protein comprising SEQ ID NO: 2 and SEQ ID NO: 17.
- [016] SEQ ID NO: 54 is an AAT polypeptide – IgG-Fc polypeptide fusion protein comprising SEQ ID NO: 2 and SEQ ID NO: 43.
- [017] SEQ ID NO: 55 is an AAT polypeptide – IgG-Fc polypeptide fusion protein comprising SEQ ID NO: 51 and SEQ ID NO: 7.

[154] SEQ ID NO: 56 is an AAT polypeptide – IgG4-Fc polypeptide fusion protein comprising SEQ ID NO: 48 and SEQ ID NO: 40.

[155] Each monomer of the engineered dimeric protein of the invention comprises at least one human serpin polypeptide (e.g. one or two) operably linked to a human immunoglobulin Fc polypeptide or a polypeptide that is derived from an immunoglobulin Fc polypeptide.

[156] As used herein, “operably linked” means linked as part of a continuous polypeptide chain i.e. as a fusion protein. Such engineered proteins are capable of being prepared by recombinant engineering techniques. As used herein, “operably linked” also means that the at least one human serpin polypeptide in fusion with the immunoglobulin Fc polypeptide is functional in terms of inhibiting serine protease activity.

[157] In an embodiment, the human serpin polypeptide is a human alpha- 1 antitrypsin (AAT) polypeptide or is derived from a human AAT polypeptide.

[158] In an embodiment, each monomer of the dimeric protein comprises one human serpin polypeptide.

[159] In an embodiment, each monomer of the engineered dimeric protein comprises at least one (e.g. one) polypeptide selected from a human alpha- 1 antitrypsin (AAT) polypeptide and polypeptides which are derived from a human AAT polypeptide wherein said at least one polypeptide is (are) operably linked to the N-terminal end of the human immunoglobulin Fc polypeptide or a polypeptide that is derived from an immunoglobulin Fc polypeptide.

[160] For example, the or each polypeptide which is a human alpha- 1 antitrypsin (AAT) polypeptide or is derived from a human AAT polypeptide that has the sequence of SEQ ID NOs: 1 or 2.

[161] For example, the or each polypeptide which is a human alpha-1 antitrypsin (AAT) or is derived from a human AAT polypeptide has the sequence of SEQ ID NO: 1. For example, the or each polypeptide which is a human alpha-1 antitrypsin (AAT) or is derived from a human AAT polypeptide has a sequence that is at least 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 1.

[162] In some embodiments, a full-length human AAT polypeptide sequence has the following amino acid sequence:

```

1  EDPQGDAAQK TDTSHHDQDH PTFNKITPNL AEFAFSLYRQ LAHQSNSTNI FFSPVSIATA
61  FAMLSTGKA DTHDEILEGL NFNLTETPEA QIHEGFQELL RTLNQPDSQL QLTTGNGLFL
121 SEGLKLVDKF LEDVKKLYHS EAFTVNFQDT EEAKKQINDY VEKGTQGKIV DLVKELDRDT
181 VFALVNYIFF KGKWERPFEV KDTEEDDFHV DQVTTVKVPM MKRLGMFNIQ HCKKLSSWVL
241 LMKYLGDATA IFFLPDEGKL QHLENELTHD IITKFLENED RRSASLHLPK LSITGTYDLK

```

301 SVLGQLGITK VFSNGADLSG VTEEAPLKLS KAVHKAVLTI DEKGTEAAGA MFLEAIPMSI
 361 PPEVKFNKPF VFLMIEQNTK SPLFMGKVVN PTQK (SEQ ID NO: 1)

[163] For example, the or each polypeptide which is a human alpha-1 antitrypsin (AAT) or is derived from a human AAT polypeptide has the sequence of SEQ ID NO: 2. For example, the or each polypeptide which is a human alpha-1 antitrypsin (AAT) or is derived from a human AAT polypeptide has a sequence that is at least 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 2.

[164] In some embodiments, a full-length human AAT polypeptide sequence has the following amino acid sequence:

1 EDPQGDAQK TDTSHHDQDH PTFNKITPNL AEFAFSLYRQ LAHQSNSTNI FFSPVSIATA
 61 FAMLISLGTKA DTHDEILEGL NFNLTETPEA QIHEGFQELL RTLNQPDSQL QLTGNGFLFL
 121 SEGLKLVDKF LEDVKKLYHS EAFTVNFGDT EEAKKQINDY VEKGTQGKIV DLVKELDRDT
 181 VFALVNYIFF KGKWERPFEV KDTEEEEDFHV DQVTTVKVPM MKRLGMFNIQ HCKKLSSWVL
 241 LMKYLGNATA IFFLPDEGKL QHLENELTHD IITKFLENED RRSASLHLPK LSITGTYDLK
 301 SVLGQLGITK VFSNGADLSG VTEEAPLKLS KAVHKAVLTI DEKGTEAAGA EFLEAIPLSI
 361 PPEVKFNKPF VFLMIEQNTK SPLFMGKVVN PTQK (SEQ ID NO: 2)

[165] For example, the or each polypeptide which is a human alpha-1 antitrypsin (AAT) or is derived from a human AAT polypeptide sequences has a sequence shown in GenBank Accession Nos. AAB59495.1, CAJ15161.1, P01009.3, AAB59375.1, AAA51546.1, CAA25838.1, NP_001002235.1, CAA34982.1, NP_001002236.1, NP_000286.3, NP_001121179.1, NP_001121178.1, NP_001121177.1, NP_001121176.16, NP_001121175.1, NP_001121174.1, NP_001121172.1, and/or AAA51547.1.

[166] For example, the or each polypeptide which is a human alpha- 1 antitrypsin (AAT) polypeptide comprises a reactive loop sequence according to any one of the sequence of SEQ ID NOs: 3, 4 and 5.

[167] In some embodiments, the reactive site loop portion of the AAT protein includes at least the amino acid sequence: GTEAAGAMFLEAIPMSIPPEVKFNK (SEQ ID NO: 3). In some embodiments, the reactive site loop portion of the AAT protein includes at least the amino acid sequence: GTEAAGAEFLEAIPMSIPPEVKFNK (SEQ ID NO: 4). In some embodiments, the reactive site loop portion of the AAT protein includes at least the amino acid sequence: GTEAAGALFLEAIPMSIPPEVKFNK (SEQ ID NO: 5).

[168] In an embodiment, the polypeptide comprises human immunoglobulin Fc polypeptide or a polypeptide that is derived from an immunoglobulin Fc polypeptide is a human IgG1 Fc

polypeptide. In some embodiments the human IgG1 Fc polypeptide sequence has the following amino acid sequence:

```

1  APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK
61  PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT
121 LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTTPVLDS DGSFFLYSKL
181 TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK (SEQ ID NO: 6)

```

[169] In some embodiments, the polypeptide includes a hinge region coupled to the N-terminus of the Fc polypeptide of the polypeptide, where the Fc polypeptide includes a human IgG1 Fc polypeptide sequence having the following amino acid sequence:

```

1  DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD
61  GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK
121 GQPREPQVYT LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTTPVLDS
181 DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK (SEQ ID NO: 7)

```

[170] In some embodiments where the polypeptide of the invention includes an Fc polypeptide, the Fc polypeptide of the polypeptide includes a human IgG1 Fc polypeptide sequence that is at least 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 6 or 7.

[171] In some embodiments, the polypeptide of the invention includes a modified IgG1 Fc polypeptide, the modified IgG1 Fc polypeptide of the fusion protein includes mutations at residues M252, T256, and M428, which correspond to residues 22, 26, and 198 of SEQ ID NO: 6 or residues 32, 36, and 208 of SEQ ID NO: 7 shown above, and has the following amino acid sequence, where the mutated amino acid residues are boxed:

```

1  APELLGGPSV FLFPPKPKDT LIISRDPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK
61  PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT
121 LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTTPVLDS DGSFFLYSKL
181 TVDKSRWQQG NVFSCSVIHE ALHNHYTQKS LSLSPGK (SEQ ID NO: 8)

```

[172] In some embodiments, the polypeptide of the invention includes a hinge region coupled to the N-terminus of a modified IgG1 Fc polypeptide, the modified IgG1 Fc polypeptide of the fusion protein includes mutations at residues M252, T256, and M428, which correspond to residues 22, 26, and 198 of SEQ ID NO: 6 or residues 32, 36, and 208 of SEQ ID NO: 7 shown above, and the fusion protein includes at least the following amino acid sequence, where the mutated amino acid residues are boxed:

1 DKTHTCPPCP APELLGGPSV FLFPPKPKDT L¹ISR¹PEVT CVVVDVSHED PEVKFNWYVD
 61 GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK
 121 GQPREPQVYT LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTPPVLDSD
 181 DGSFFLYSKL TVDKSRWQQG NVFSCSV¹HE ALHNHYTQKS LSLSPGK (SEQ ID NO: 9)

[173] In some embodiments, the polypeptide of the invention includes a modified IgG1 Fc polypeptide, the modified IgG1 Fc polypeptide of the fusion protein includes a modified human IgG1 Fc polypeptide sequence where residue G236, which corresponds to residue 6 of SEQ ID NO: 6 or residue 16 of SEQ ID NO: 7 shown above, is deleted and has the following amino acid sequence:

1 APELLGPSVF LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP
 61 REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC KVSNAKALPA IEKTISKAKG QPREPQVYTL
 121 PPSRDELTKN QVSLTCLVKG FYPSDIAVEW ESNQGPENNY KTPPVLDSD GSFFLYSKLT
 181 VDKSRWQQGN VFSCSV¹MHEA LHNHYTQKSL SLSPGK (SEQ ID NO: 10)

[174] In some embodiments, the polypeptide of the invention includes a hinge region coupled to the N-terminus of a modified IgG1 Fc polypeptide, the modified IgG1 Fc polypeptide of the fusion protein includes a modified human IgG1 Fc polypeptide sequence where residue G236, which corresponds to residue 6 of SEQ ID NO: 6 or residue 16 of SEQ ID NO: 7 shown above, is deleted, and the fusion protein includes at least the following amino acid sequence:

1 DKTHTCPPCP APELLGPSVF LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVKFNWYVDG
 61 VEVHNAKTKP REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC KVSNAKALPA IEKTISKAKG
 121 QPREPQVYTL PPSRDELTKN QVSLTCLVKG FYPSDIAVEW ESNQGPENNY KTPPVLDSD
 181 GSFFLYSKLT VDKSRWQQGN VFSCSV¹MHEA LHNHYTQKSL SLSPGK (SEQ ID NO: 11)

[175] In some embodiments, the polypeptide of the invention includes a modified IgG1 Fc polypeptide, wherein the modified IgG1 Fc polypeptide of the fusion protein includes mutations at residues L234 and L235, which correspond to residues 4 and 5 of SEQ ID NO: 6 or residues 14 and 15 of SEQ ID NO: 7 shown above, and has the following amino acid sequence, where the mutated amino acid residues are boxed:

1 APE¹VAGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK
 61 PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT
 121 LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTPPVLDSD DGSFFLYSKL
 181 TVDKSRWQQG NVFSCSV¹MHE ALHNHYTQKS LSLSPGK (SEQ ID NO: 12)

[176] In some embodiments, the polypeptide of the invention includes a hinge region coupled

to the N-terminus of a modified IgG1 Fc polypeptide, the modified IgG1 Fc polypeptide of the polypeptide includes mutations at residues L234 and L235, which correspond to residues 4 and 5 of SEQ ID NO: 6 or residues 14 and 15 of SEQ ID NO: 7 shown above, and the fusion protein includes at least the following amino acid sequence, where the mutated amino acid residues are boxed:

```

1 DKHTTCPPCP APE[VA]GGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD
61 GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK
121 QPREPQVYT LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTTPVLDS
181 DGSFFLYSKL TVDKSRWQQG NVFSCSVME ALHNHYTQKS LSLSPGK (SEQ ID NO: 13)

```

[177] In some embodiments the polypeptide of the invention includes a modified IgG1 Fc polypeptide, the modified IgG1 Fc polypeptide of the fusion protein includes a deletion at residue G236 and mutations at residues L234 and L235, and the fusion protein includes at least the following amino acid sequence, where the mutated amino acid residues are boxed:

```

1 APE[VA]GPSVF LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP
61 REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC KVSNAKALPA IEKTISKAKG QPREPQVYTL
121 PPSRDELTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTTPVLDS DGSFFLYSKLT
181 VDKSRWQQGN VFSCSVMEAL LHNHYTQKSL SLSPGK (SEQ ID NO: 14)

```

[178] In some embodiments, the polypeptide of the invention includes a hinge region coupled to the N-terminus of a modified IgG1 Fc polypeptide, the modified IgG1 Fc polypeptide of the fusion protein includes a deletion at residue G236 and mutations at residues L234 and L235, and has the following amino acid sequence, where the mutated amino acid residues are boxed:

```

1 DKHTTCPPCP APE[VA]GPSVF LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVKFNWYVDG
61 VEVHNAKTKP REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC KVSNAKALPA IEKTISKAKG
121 QPREPQVYTL PPSRDELTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTTPVLDS
181 GSFFLYSKLT VDKSRWQQGN VFSCSVMEAL LHNHYTQKSL SLSPGK (SEQ ID NO: 15)

```

[179] In some embodiments, the polypeptide of the invention includes a modified IgG1 Fc polypeptide, the modified IgG1 Fc polypeptide of the fusion protein includes a deletion at residue G236 and mutations at residues L234, L235, M252, T256, and M428, and the fusion protein includes at least the following amino acid sequence, where the mutated amino acid residues are boxed:

```

1 APE[VA]GPSVF LFPPKPKDTL [T]ISR[D]PEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP

```

61 REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC KVS NKALPAP IEKTISKAKG QPREPQVYTL
 121 PPSRDELTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTTPVLDSG GSFFLYSKLT
 181 VDKSRWQQGN VFSCSVLHEA LHNHYTQKSL SLSPGK (SEQ ID NO: 16)

[180] In some embodiments, polypeptide of the invention includes a hinge region coupled to the N-terminus of a modified IgG1 Fc polypeptide, the modified IgG1 Fc polypeptide of the fusion protein includes a deletion at residue G236 and mutations at residues L234, L235, M252, T256, and M428, and has the following amino acid sequence, where the mutated amino acid residues are boxed:

1 DKTHTCPPCP APEVAGPSVF LFPPKPKDTL TISRDEVTTC VVVDVSHEDP EVKFNWYVDG
 61 VEVHNAKTKP REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC KVS NKALPAP IEKTISKAKG
 121 QPREPQVYTL PPSRDELTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTTPVLDSG
 181 GSFFLYSKLT VDKSRWQQGN VFSCSVLHEA LHNHYTQKSL SLSPGK (SEQ ID NO: 17)

[181] In some embodiments, the polypeptide of the invention includes a modified IgG1 Fc polypeptide, the modified IgG1 Fc polypeptide of the fusion protein includes a modified human IgG1 Fc polypeptide sequence that is at least 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17.

[182] In some embodiments, the polypeptide of the invention includes an Fc polypeptide, the Fc polypeptide of the fusion protein includes a human IgG2 Fc polypeptide sequence having the following amino acid sequence:

1 APPVAGPSVF LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVQFNWYVDG VEVHNAKTKP
 61 REEQFNSTFR VVSVLTVVHQ DWLNGKEYKC KVS NKGLPAP IEKTISKTKG QPREPQVYTL
 121 PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTTPMLDSG GSFFLYSKLT
 181 VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK (SEQ ID NO: 18)

[183] In some embodiments where the fusion protein of the invention includes an Fc polypeptide, the Fc polypeptide of the fusion protein includes a human IgG2 Fc polypeptide sequence that is at least 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 18.

[184] In some embodiments, the polypeptide of the invention includes a modified IgG2 Fc polypeptide, the modified IgG2 Fc polypeptide of the fusion protein includes a deletion at residue G236 and mutations at residues M252, T256, and M428, and has the following amino acid sequence, where the mutated amino acid residues are boxed:

1 APPVAGPSVF LFPPKPKDTL TISRDEVTTC VVVDVSHEDP EVQFNWYVDG VEVHNAKTKP

61 REEQFNSTFR VVSVLTVVHQ DWLNGKEYKC KVSNGKLPAP IEKTISKTKG QPREPQVYTL
 121 PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTTPMLDSD GSFFLYSKLT
 181 VDKSRWQQGN VFSCSVLHEA LHNHYTQKSL SLSPGK (SEQ ID NO: 19)

[185] In some embodiments, the polypeptide of the invention includes an Fc polypeptide, the Fc polypeptide of the fusion protein includes a human IgG3 Fc polypeptide sequence having the following amino acid sequence:

1 APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVQFKWYVD GVEVHNAKTK
 61 PREEQYNSTF RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKTK GQPREPQVYT
 121 LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESSGQPENN YNTTPMLDS DGSFFLYSKL
 181 TVDKSRWQQG NIFSCSVMHE ALHNRFTQKS LSLSPGK (SEQ ID NO: 20)

[186] In some embodiments, the polypeptide of the invention includes an Fc polypeptide, the Fc polypeptide of the fusion protein includes a human IgG3 Fc polypeptide sequence that is at least 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 20.

[187] In some embodiments, the polypeptide of the invention includes a modified IgG3 Fc polypeptide, the modified IgG3 Fc polypeptide of the fusion protein includes mutations at residues M252, T256, and M428, and has the following amino acid sequence, where the mutated amino acid residues are boxed:

1 APELLGGPSV FLFPPKPKDT L^IISR^DPEVT CVVVDVSHED PEVQFKWYVD GVEVHNAKTK
 61 PREEQYNSTF RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKTK GQPREPQVYT
 121 LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESSGQPENN YNTTPMLDS DGSFFLYSKL
 181 TVDKSRWQQG NIFSCSV^LHE ALHNRFTQKS LSLSPGK (SEQ ID NO: 21)

[188] In some embodiments, the polypeptide of the invention includes a modified IgG3 Fc polypeptide, the modified IgG3 Fc polypeptide of the fusion protein includes a modified human IgG3 Fc polypeptide sequence where residue G236, which corresponds to residue 6 of SEQ ID NO: 20 shown above, is deleted and has the following amino acid sequence:

1 APELLGPSVF LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVQFKWYVDG VEVHNAKTKP
 61 REEQYNSTFR VVSVLTVLHQ DWLNGKEYKC KVSNGKLPAP IEKTISKTKG QPREPQVYTL
 121 PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESSGQPENNY NTPPMLDSD GSFFLYSKLT
 181 VDKSRWQQGN IFSCSVMHEA LHNRF^TQKSL SLSPGK (SEQ ID NO: 22)

[189] In some embodiments, the polypeptide of the invention includes a modified IgG3 Fc polypeptide, the modified IgG3 Fc polypeptide of the fusion protein includes mutations at

residues L234 and L235, which correspond to residues 4 and 5 of SEQ ID NO: 20 shown above, and has the following amino acid sequence, where the mutated amino acid residues are boxed:

```

1 APEVAGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVQFKWYVD GVEVHNAKTK
61 PREEQYNSTF RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKTK GQPREPQVYT
121 LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESSGQPENN YNTTPPMLDS DGSFFLYSKL
181 TVDKSRWQQG NIFSCSVMHE ALHNRFTQKS LSLSPGK (SEQ ID NO: 23)

```

[190] In some embodiments where the fusion protein of the invention includes a modified IgG3 Fc polypeptide, the modified IgG3 Fc polypeptide of the fusion protein includes a deletion at residue G236 and mutations at residues L234 and L235 and has the following amino acid sequence:

```

1 APEVAGGPSVF LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVQFKWYVDG VEVHNAKTKP
61 REEQYNSTFR VVSVLTVLHQ DWLNGKEYKC KVSNAKALPAP IEKTISKTKG QPREPQVYTL
121 PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESSGQPENNY NTTPPMLDSD GSFFLYSKLT
181 VDKSRWQQGN IFSCSVMHEA LHNRFQKSL SLSPGK (SEQ ID NO: 24)

```

[191] In some embodiments, the polypeptide of the invention includes a modified IgG3 Fc polypeptide, the modified IgG3 Fc polypeptide of the fusion protein includes a deletion at residue G236 and mutations at residues L234, L235, M252, T256, and M428, and has the following amino acid sequence:

```

1 APEVAGGPSVF LFPPKPKDTL TISRPEVTC VVVDVSHEDP EVQFKWYVDG VEVHNAKTKP
61 REEQYNSTFR VVSVLTVLHQ DWLNGKEYKC KVSNAKALPAP IEKTISKTKG QPREPQVYTL
121 PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESSGQPENNY NTTPPMLDSD GSFFLYSKLT
181 VDKSRWQQGN IFSCSVTHEA LHNRFQKSL SLSPGK (SEQ ID NO: 25)

```

[192] In some embodiments, the polypeptide of the invention includes a modified IgG3 Fc polypeptide, the modified IgG3 Fc polypeptide of the fusion protein includes a modified human IgG3 Fc polypeptide sequence that is at least 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 21, 22, 23, 24, or 25.

[193] In some embodiments, the polypeptide of the invention includes an Fc polypeptide, the Fc polypeptide of the fusion protein includes a human IgG4 Fc polypeptide sequence having the following amino acid sequence:

```

1 APEFLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSQED PEVQFNWYVD GVEVHNAKTK

```

61 PREEQFNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS SIEKTISKAK GQPREPQVYT
 121 LPPSQEEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTPPVLDSDGSFFLYSRL
 181 TVDKSRWQEG NVFSCSVMHE ALHNHYTQKS LSLSLGK (SEQ ID NO: 26)

[194] In some embodiments, the polypeptide of the invention includes an Fc polypeptide, the Fc polypeptide of the fusion protein includes a hinge region coupled to the N-terminus of the Fc polypeptide of the fusion protein, where the Fc polypeptide includes a human IgG4 Fc polypeptide sequence having the following amino acid sequence:

1 ESKYGPPCPS CPAPEFLGGP SVFLFPPKPK DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY
 61 VDGVEVHNAK TKPREEQFNS TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK
 121 AKGQPREPQV YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTPPVLD
 181 DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLGK (SEQ ID NO: 27)

[195] In some embodiments, where the fusion protein of the invention includes an Fc polypeptide, the Fc polypeptide of the fusion protein includes a human IgG4 Fc polypeptide sequence that is at least 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 26 or 27.

[196] In some embodiments where the fusion protein of the invention includes a modified IgG4 Fc polypeptide, the modified IgG4 Fc polypeptide of the fusion protein includes mutations at residues M252, T256, and M428, which correspond to residues 22, 26, and 19 of SEQ ID NO: 26 or residues 34, 38, and 210 of SEQ ID NO: 27 shown above, and has the following amino acid sequence, where the mutated amino acid residues are boxed:

1 APEFLGGPSV FLFPPKPKDT L¹ISR²PEVT CVVVDVSQED PEVQFNWYVD GVEVHNAKTK
 61 PREEQFNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS SIEKTISKAK GQPREPQVYT
 121 LPPSQEEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTPPVLDSDGSFFLYSRL
 181 TVDKSRWQEG NVFSCSV³HE ALHNHYTQKS LSLSLGK (SEQ ID NO: 28)

[197] In some embodiments, the polypeptide of the invention includes a hinge region coupled to the N-terminus of a modified IgG4 Fc polypeptide, the modified IgG4 Fc polypeptide of the fusion protein includes mutations at residues M252, T256, and M428, which correspond to residues 22, 26, and 197 of SEQ ID NO: 26 or residues 34, 38, and 210 of SEQ ID NO: 27 shown above, and the fusion protein includes at least the following amino acid sequence, where the mutated amino acid residues are boxed:

1 ESKYGPPCPS CPAPEFLGGP SVFLFPPKPK DTL¹ISR²PE VTCVVVDVSQ EDPEVQFNWY
 61 VDGVEVHNAK TKPREEQFNS TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK
 121 AKGQPREPQV YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTPPVLD

181 DSDGSFFLYS RLTVDKSRWQ EGNVFSCSV[] HEALHNHYTQ KSLSLSLGK (SEQ ID NO: 29)

[198] In some embodiments, the polypeptide of the invention includes a modified IgG4 Fc polypeptide, the modified IgG4 Fc polypeptide of the fusion protein includes a modified human IgG4 Fc polypeptide sequence where residue G236, which corresponds to residue 6 of SEQ ID NO: 26 or residue 19 of SEQ ID NO: 27 shown above, is deleted and has the following amino acid sequence:

1 APEFLGPSVF LFPPKPKDTL MISRTPEVTC VVVDVSQEDP EVQFNWYVDG VEVHNAKTKP
61 REEQFNSTYR VVSVLTVLHQ DWLNGKEYKC KVSNGKLPSS IEKTISKAKG QPREPQVYTL
121 PPSQEEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTTPVLDS GSFFLYSRLT
181 VDKSRWQEGN VFSCSVMEHA LHNHYTQKSL SLSLGLK (SEQ ID NO: 30)

[199] In some embodiments, the polypeptide of the invention includes a hinge region coupled to the N-terminus of a modified IgG4 Fc polypeptide, the modified IgG4 Fc polypeptide of the fusion protein includes a modified human IgG4 Fc polypeptide sequence where residue G236, which corresponds to residue 6 of SEQ ID NO: 26 or residue 19 of SEQ ID NO: 27 shown above, is deleted, and the fusion protein includes at least the following amino acid sequence:

1 ESKYGPPCPS CPAPEFLGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSQE DPEVQFNWYV
61 DGVEVHNAKT KPREEQFNST YRVVSVLTVL HQDWLNGKEY KCKVSNKGLP SSIKTISKA
121 KGQPREPQVY TLPPSQEEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTTPVLDS
181 SDGSFFLYSR LTVDKSRWQE GNVFSCSVMH EALHNHYTQK SLSLGLK (SEQ ID NO: 31)

[200] In some embodiments, the polypeptide of the invention includes a modified IgG4 Fc polypeptide, the modified IgG4 Fc polypeptide of the fusion protein includes a mutation at residue L235, which corresponds to residue 5 of SEQ ID NO: 26 or residue 17 of SEQ ID NO: 27 shown above, and has the following amino acid sequence, where the mutated amino acid residue is boxed:

1 APEF[]GGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSQED PEVQFNWYVD GVEVHNAKTK
61 PREEQFNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS SIEKTISKAK GQPREPQVYT
121 LPPSQEEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTTPVLDS DGSFFLYSRL
181 TVDKSRWQEG NVFSCSVME ALHNHYTQKS LSLSLGLK (SEQ ID NO: 32)

[201] In some embodiments, the polypeptide of the invention includes a hinge region coupled to the N-terminus of a modified IgG4 Fc polypeptide, the modified IgG4 Fc polypeptide of the fusion protein includes a mutation at residue L235, which corresponds to residue 5 of SEQ ID NO: 26 or residue 17 of SEQ ID NO: 27 shown above, and the fusion protein includes at least the following amino acid sequence, where the mutated amino acid residue is boxed:

1 ESKYGPPCPS CPAPEF**E**GGP SVFLFPPKPK DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY
 61 VDGVEVHNAK TKPREEQFNS TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK
 121 AKGQPREPQV YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL
 181 DSDGSFFLYS RLTVDKSRWQ EGNVFSCSV MHEALHNHYTQ KSLSLSLGK (SEQ ID NO: 33)

[202] In some embodiments, the polypeptide of the invention includes a modified IgG4 Fc polypeptide, the modified IgG4 Fc polypeptide of the fusion protein includes mutations at residues L234 and L235, which correspond to residues 4 and 5 of SEQ ID NO: 26 or residues 16 and 17 of SEQ ID NO: 27 shown above, and has the following amino acid sequence, where the mutated amino acid residues are boxed:

1 APE**V**AGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSQED PEVQFNWYVD GVEVHNAKTK
 61 PREEQFNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS SIEKTISKAK GQPREPQVYT
 121 LPPSQEEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLD SGSFFLYSRL
 181 TVDKSRWQEG NVFSCSV MHEALHNHYTQKS LSLSLGK (SEQ ID NO: 34)

[203] In some embodiments, the polypeptide of the invention includes a hinge region coupled to the N-terminus of a modified IgG4 Fc polypeptide, the modified IgG4 Fc polypeptide of the fusion protein includes mutations at residues L234 and L235, which correspond to residues 4 and 5 of SEQ ID NO: 26 or residues 16 and 17 of SEQ ID NO: 27 shown above, and the fusion protein includes at least the following amino acid sequence, where the mutated amino acid residues are boxed:

1 ESKYGPPCPS CPAPE**V**AGGP SVFLFPPKPK DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY
 61 VDGVEVHNAK TKPREEQFNS TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK
 121 AKGQPREPQV YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL
 181 DSDGSFFLYS RLTVDKSRWQ EGNVFSCSV MHEALHNHYTQ KSLSLSLGK (SEQ ID NO: 35)

[204] In some embodiments, the polypeptide of the invention includes a modified IgG4 Fc polypeptide, the modified IgG4 Fc polypeptide of the fusion protein includes a mutation at residue S228, which corresponds to residue 10 of SEQ ID NO: 27 shown above, and has the following amino acid sequence, where the mutated amino acid residue is boxed:

1 ESKYGPPCP**E** CPAPEFLGGP SVFLFPPKPK DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY
 61 VDGVEVHNAK TKPREEQFNS TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK
 121 AKGQPREPQV YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL
 181 DSDGSFFLYS RLTVDKSRWQ EGNVFSCSV MHEALHNHYTQ KSLSLSLGK (SEQ ID NO: 36)

[205] In some embodiments, the polypeptide of the invention includes a hinge region coupled

to the N-terminus of a modified IgG4 Fc polypeptide, the modified IgG4 Fc polypeptide of the fusion protein includes mutations at residues S228 and L235, which correspond to residues 10 and 17 of SEQ ID NO: 27 shown above, and the fusion protein includes at least the following amino acid sequence, where the mutated amino acid residues are boxed:

```

1  ESKYGPPCP[P] CPAPEF[E]GGP SVFLFPPKPK DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY
61 VDGVEVHNAK TKPREEQFNS TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK
121 AKGQPREPQV YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL
181 DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLGK (SEQ ID NO: 37)

```

[206] In some embodiments, the polypeptide of the invention includes a hinge region coupled to the N-terminus of a modified IgG4 Fc polypeptide, the modified IgG4 Fc polypeptide of the fusion protein includes mutations at residues S228, L235 and M252 which correspond to residues 10, 17 and 34 of SEQ ID NO: 27 shown above, and the fusion protein includes at least the following amino acid sequence, where the mutated amino acid residues are boxed:

```

1  ESKYGPPCP[P] CPAPEF[E]GGP SVFLFPPKPK DTLYISRTPE VTCVVVDVSQ EDPEVQFNWY
61 VDGVEVHNAK TKPREEQFNS TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK
121 AKGQPREPQV YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL
181 DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVL HEALHNHYTQ KSLSLSLGK (SEQ ID NO: 38)

```

[207] In some embodiments, the polypeptide of the invention includes a hinge region coupled to the N-terminus of a modified IgG4 Fc polypeptide, the modified IgG4 Fc polypeptide of the fusion protein includes mutations at residues S228, L235 and M428 which correspond to residues 10, 17 and 34 of SEQ ID NO: 27 shown above, the fusion protein includes at least the following amino acid sequence, where the mutated amino acid residues are boxed:

```

1  ESKYGPPCP[P] CPAPEF[E]GGP SVFLFPPKPK DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY
61 VDGVEVHNAK TKPREEQFNS TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK
121 AKGQPREPQV YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL
181 DSDGSFFLYS RLTVDKSRWQ EGNVFSCSV[L] HEALHNHYTQ KSLSLSLGK (SEQ ID NO: 39)

```

[208] In some embodiments, the polypeptide of the invention includes a hinge region coupled to the N-terminus of a modified IgG4 Fc polypeptide, the modified IgG4 Fc polypeptide of the fusion protein includes mutations at residues S228, L235, M252 and M428 which correspond to residues 10, 17, 34 and 210 of SEQ ID NO: 27 shown above, the fusion protein includes at least the following amino acid sequence, where the mutated amino acid residues are boxed:

```

1  ESKYGPPCP[P] CPAPEF[E]GGP SVFLFPPKPK DTLYISRTPE VTCVVVDVSQ EDPEVQFNWY

```

61 VDGVEVHNAK TKPREEQFNS TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK
 121 AKGQPREPQV YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTTPVL
 181 DSDGSFFLYS RLTVDKSRWQ EGNVFSCSV^L HEALHNHYTQ KSLSLSLGK (SEQ ID NO: 40)

[209] In some embodiments, the polypeptide of the invention includes a modified IgG4 Fc polypeptide, the modified IgG4 Fc polypeptide of the fusion protein includes mutations at residues L235, M252, T256, and M428, which correspond to residues 5, 22, 26, and 197 of SEQ ID NO: 26 or residues 17, 34, 38, and 210 of SEQ ID NO: 27 shown above, and has the following amino acid sequence, where the mutated amino acid residues are boxed:

1 APEF^EGGPSV FLFPKPKDT L^IISR^DPEVT CVVVDVSQED PEVQFNWYVD GVEVHNAKTK
 61 PREEQFNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS SIEKTISKAK GQPREPQVYT
 121 LPPSQEEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTTPVLDS DGSFFLYSRL
 181 TVDKSRWQEG NVFSCSV^LHE ALHNHYTQKS LSLSLGK (SEQ ID NO: 41)

[210] In some embodiments, the polypeptide of the invention includes a hinge region coupled to the N-terminus of a modified IgG4 Fc polypeptide, the modified IgG4 Fc polypeptide of the fusion protein includes mutations at residues L235, M252, T256, and M428, which correspond to residues 5, 22, 26, and 197 of SEQ ID NO: 26 or residues 17, 34, 38, and 210 of SEQ ID NO: 27 shown above, and the fusion protein includes at least the following amino acid sequence, where the mutated amino acid residues are boxed:

1 ESKYGPPCPS CPAPEF^EGGP SVFLFPKPK DTL^IISR^DPE VTCVVVDVSQ EDPEVQFNWY
 61 VDGVEVHNAK TKPREEQFNS TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK
 121 AKGQPREPQV YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTTPVL
 181 DSDGSFFLYS RLTVDKSRWQ EGNVFSCSV^L HEALHNHYTQ KSLSLSLGK (SEQ ID NO: 42)

[211] In some embodiments, the polypeptide of the invention includes a hinge region coupled to the N-terminus of a modified IgG4 Fc polypeptide, the modified IgG4 Fc polypeptide of the fusion protein includes mutations at residues S228, L235, M252, T256, and M428, which correspond to residues 10, 17, 34, 38, and 210 of SEQ ID NO: 27 shown above, and the fusion protein includes at least the following amino acid sequence, where the mutated amino acid residues are boxed:

1 ESKYGPPCP^E CPAPEF^EGGP SVFLFPKPK DTL^IISR^DPE VTCVVVDVSQ EDPEVQFNWY
 61 VDGVEVHNAK TKPREEQFNS TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK
 121 AKGQPREPQV YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTTPVL
 181 DSDGSFFLYS RLTVDKSRWQ EGNVFSCSV^L HEALHNHYTQ KSLSLSLGK (SEQ ID NO: 43)

[212] In some embodiments where the fusion protein of the invention includes a modified IgG4 Fc polypeptide, the modified IgG4 Fc polypeptide of the fusion protein includes a modified human IgG4 Fc polypeptide sequence that is at least 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42 or 43.

[213] For example, the human immunoglobulin Fc polypeptide or a polypeptide that is derived from an immunoglobulin Fc polypeptide is a modified human IgG4 Fc polypeptide that has the sequence of SEQ ID NO: 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42 or 43.

[214] In some embodiments, the polypeptide of the invention includes an Fc polypeptide that is derived from a modified human IgG4 Fc polypeptide, wherein the modified human IgG4 Fc polypeptide comprises mutations at positions S228, L235, M252, T256, and M428.

[215] In some embodiments, the polypeptide of the invention includes a modified human IgG4 Fc polypeptide, wherein the modified human IgG4 Fc polypeptide comprises the amino acid sequence of SEQ ID NOs: 27, 36 or 37, wherein the modified human IgG4 Fc polypeptide comprises a mutation at position M252 (residue 34 of SEQ ID NO: 27) and/or at position, M428, (residue 210 of SEQ ID NO: 27).

[216] In an embodiment, the modified human IgG4 Fc polypeptide further comprises a mutations at position T256 (residue 38 of SEQ ID NO: 27).

[217] In some embodiments, the polypeptide of the invention includes an Fc polypeptide, the Fc polypeptide of the fusion protein includes a human IgM Fc polypeptide sequence having the following amino acid sequence:

```

1  IAELPPKVSF FVPPRDGFFG NPRKSKLICQ ATGFSPRQIQ VSWLREGKQV GSGVTTDQVQ
61  AEAKESGPTT YKVTSTLTIK ESDWLGQSMF TCRVDHRGLT FQQNASSMCV PDQDTAIRVF
121 AIPPSFASIF LTKSTKLTL VTDLTYYDSV TISWTRQNGE AVKTHTNISE SHPNATFSAV
181 GEASICEDDW NSGERFTCTV THTDLPSPK QTISRPKG (SEQ ID NO: 44)

```

[218] In an embodiment, the human immunoglobulin Fc polypeptide or a polypeptide that is derived from an immunoglobulin Fc polypeptide is a modified human IgG4 Fc polypeptide.

[219] In an embodiment, each monomer of the dimeric protein has the sequence of SEQ ID No: 45. As shown below, AAT polypeptide portion of the fusion protein is underlined (SEQ ID NO: 1) and the IgG-Fc polypeptide portion of the fusion protein is italicized (SEQ ID NO: 6).

EDPQGDAAQKTDTSHHDDHPTFNKITPNLAEFAFSLYRQLAHQSNSTNIFFSPVSIATAFA
MLSLGTKADTHDEILEGLNFNLTEIPEAQIHEGFQELLRTLNQPDSQLQLTTGNGLFLSEGL
KLVDKFLEDVKKLYHSEAFTVNFGDTEEAKKQINDYVEKGTQGKIVDLVKELDRDTVFALVN

YIFFKGKWERPFEVKDTEEEEDFHVDQVTTVKVPMMKRLGMFNIQHCKKLSSWVLLMKYLGNA
TAIFFLPDEGKLQHLENELTHDIIITKFLNEDRRSASLHLPKLSITGTYDLKSVLGQLGITK
VFSNGADLSGVTEEAPLKLSKAVHKAVLTIDEKGTEAAGAMFLEAIPMSIPPEVKFNKPFVF
LMIEQNTKSPLFMGKVVNPTQKEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR
TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK
EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAV
EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSFSVMHEALHNHYTQKSL
SLSPGK (SEQ ID NO: 45)

[220] In an embodiment, each monomer of the dimeric protein has the sequence of SEQ ID No: 46. As shown below, AAT polypeptide portion of the fusion protein is underlined (SEQ ID NO: 1) and the IgG-Fc polypeptide portion of the fusion protein is italicized (SEQ ID NO: 18).

EDPQGDAQAQKTDTSHHQDHPTFNKIITPNLAEEFAFSLYRQLAHQSNSTNIIFFSPVSIATAFA
MLSLGKADTHDEIILEGLNFNLTETPEAQIHEGFQELLRLTNQPDSQLQLTTGNGFLFLSEGL
KLVDKFLEDVKKLYHSEAFTVNFGDTEEAQKQINDYVEKGTQGGKIVDLVKELDRDITVFALVN
YIFFKGKWERPFEVKDTEEEEDFHVDQVTTVKVPMMKRLGMFNIQHCKKLSSWVLLMKYLGNA
TAIFFLPDEGKLQHLENELTHDIIITKFLNEDRRSASLHLPKLSITGTYDLKSVLGQLGITK
VFSNGADLSGVTEEAPLKLSKAVHKAVLTIDEKGTEAAGAMFLEAIPMSIPPEVKFNKPFVF
LMIEQNTKSPLFMGKVVNPTQKERKCCVECPAPVAGPSVFLFPPKPKDTLMISR
TPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVSVLTVVHQDWLNGKEYKC
KVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWES
NGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSFSVMHEALHNHYTQKSLSLSP
GK (SEQ ID NO: 46)

[221] In an embodiment each monomer of the dimeric protein has the sequence of SEQ ID No: 47. As shown below, AAT polypeptide portion of the fusion protein is underlined (SEQ ID NO: 48), the IgG-Fc polypeptide portion of the fusion protein is italicized (SEQ ID NO: 6), and the Met351Glu mutation is boxed, and the Met358Leu mutation is shaded in grey.

EDPQGDAQAQKTDTSHHQDHPTFNKIITPNLAEEFAFSLYRQLAHQSNSTNIIFFSPVSIATAFA
MLSLGKADTHDEIILEGLNFNLTETPEAQIHEGFQELLRLTNQPDSQLQLTTGNGFLFLSEGL
KLVDKFLEDVKKLYHSEAFTVNFGDTEEAQKQINDYVEKGTQGGKIVDLVKELDRDITVFALVN
YIFFKGKWERPFEVKDTEEEEDFHVDQVTTVKVPMMKRLGMFNIQHCKKLSSWVLLMKYLGNA
TAIFFLPDEGKLQHLENELTHDIIITKFLNEDRRSASLHLPKLSITGTYDLKSVLGQLGITK
VFSNGADLSGVTEEAPLKLSKAVHKAVLTIDEKGTEAAGAEFLEAIPISIPPEVKFNKPFVF
LMIEQNTKSPLFMGKVVNPTQKEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR

*TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK
EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAV
EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVVFSCSVMHEALHNHYTQKSL
SLSPGK* (SEQ ID NO: 47)

[222] In an embodiment each monomer of the dimeric protein has the sequence of SEQ ID No: 49. As shown below, AAT polypeptide portion of the fusion protein is underlined (SEQ ID NO: 48), the IgG-Fc polypeptide portion of the fusion protein is italicized (SEQ ID NO: 18), the Met351Glu mutation is boxed, and the Met358Leu mutation is shaded in grey.

*EDPQGDAAQKTDTS³⁵¹HHQDHPTFNKITPNLAEFAFSLYRQLAHQSNSTNIFFSPVSIATAFA
MLSLG³⁵⁸TKADTHDEILEGLNFNLTETPEAQIHEGFQELLRTLNQPDSQLQLTTGNGLFLSEGL
KLVDKFLEDVKKLYHSEAFTVNFGDTEEAKKQINDYVEKGTQGKIVDLVKELDRDTV³⁵¹FALVN
YIFFKGKWERPFEVKDTEEDFHVDQVTTVKVPMMKRLGMFNIQHCKKLSSWVLLMKYLGNA
TAIFFLPDEGKLQHLENELTHDIIITKFLNEDRRSASLHLPKLSITGTYDLKSVLGQLGITK
VFSNGADLSGVTEEAPLKLSKAVHKAVLTIDEKGTEAAGA³⁵¹EFLEAIP³⁵⁸LSIPPEVKFNKPFVF
LMIEQNTKSPLFMGKVVNPTQKERKCCVECPCPAPPVAGPSVFLFPPKPKDTLMISRTPEV
TCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVS³⁵¹VLTVVHQDWLNGKEYKC
KVS³⁵⁸NKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWES
NGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVVFSCSVMHEALHNHYTQKSLSLSP
GK* (SEQ ID NO: 49)

[223] In an embodiment each monomer of the dimeric protein has the sequence of SEQ ID No: 50. As shown below, AAT polypeptide portion of the fusion protein is underlined (SEQ ID NO: 51), the IgG-Fc polypeptide portion of the fusion protein is italicized (SEQ ID NO: 18), the Met351Leu mutation is shaded in black, and the Met358Leu mutation is shaded in grey.

*EDPQGDAAQKTDTS³⁵¹HHQDHPTFNKITPNLAEFAFSLYRQLAHQSNSTNIFFSPVSIATAFA
MLSLG³⁵⁸TKADTHDEILEGLNFNLTETPEAQIHEGFQELLRTLNQPDSQLQLTTGNGLFLSEGL
KLVDKFLEDVKKLYHSEAFTVNFGDTEEAKKQINDYVEKGTQGKIVDLVKELDRDTV³⁵¹FALVN
YIFFKGKWERPFEVKDTEEDFHVDQVTTVKVPMMKRLGMFNIQHCKKLSSWVLLMKYLGNA
TAIFFLPDEGKLQHLENELTHDIIITKFLNEDRRSASLHLPKLSITGTYDLKSVLGQLGITK
VFSNGADLSGVTEEAPLKLSKAVHKAVLTIDEKGTEAAGA³⁵¹³⁵⁸EFLEAIP³⁵⁸LSIPPEVKFNKPFVF
LMIEQNTKSPLFMGKVVNPTQKERKCCVECPCPAPPVAGPSVFLFPPKPKDTLMISRTPEV
TCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVS³⁵¹VLTVVHQDWLNGKEYKC
KVS³⁵⁸NKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWES*

NGQPENNYKTTTPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP
GK (SEQ ID NO:50)

[224] In an embodiment each monomer of the dimeric protein has the sequence of SEQ ID No: 52. As shown below, AAT polypeptide portion of the fusion protein is underlined (SEQ ID NO: 1), the IgG-Fc polypeptide portion of the fusion protein is italicized (SEQ ID NO: 6).

EDPQGDAQAQKTDTSHHDDQDHPTFNKITPNLAEFAFSLYRQLAHQSNSTNIFFSPVSIATAFA
MLSLGTKADTHDEILEGLNFNLTEIPEAQIHEGFQELLRTLNQPDSQLQLTTGNGLFLSEGL
KLVDKFLEDVKKLYHSEAFTVNFGDTEEAKKQINDYVEKGTQGKIVDLVKELDRDTVFALVN
YIFFKGKWERPPFEVKDTEEEDFHVDQVTTVKVPMMKRLGMFNIQHCKKLSSWVLLMKYLGNA
TAIFFLPDEGKLQHLENELTHDIITKFLENEDRRSASLHLPKLSITGTYDLKSVLGQLGITK
VFSNGADLSGVTEEAPLKLSKAVHKAVLTIDEKGTEAAGAMFLEAIPMSIPPEVKFNKPFVF
LMIEQNTKSPLFMGKVVNPTQKEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR
*TPEV**TCV**VVDV**SHED**PEVKFN**WYVD**GVEV**HNAK**TKP**REEQ**YN**STY**RV**VS**VL**TV**LH**QD**W**L**NGK*
*EYKCK**V**SN**KAL**PAPI**EKTISK**AKGQ**PREPQ**VY**TL**PP**S**DEL**TKN**Q**V**SL**TCL**V**K**G**F**Y**P**S**D**I**A**V*
*EWES**NGQ**PENNYKTTTP**VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP*
*PGKASTG**SEDPQ**GDAQAQKTDTS**HHDDQDHPTFNKITPNLA**EFAFSLYRQLAHQSNSTNIF*
*FSPVSIATAFAM**LSL**G**TKADTHDEI**LEGLN**FNLT**EIPEAQI**HEGFQ**ELLRTL**NQPD**SQLQ**LT**TG**NGL**FL**SEGL*
*KLVDK**FLEDV**KKLYH**SEAFTV**NFGD**TEEAKKQ**INDYVEKGTQ**GKIV**DLV**KELDRD**TVFALVN*
*YI**FFKG**KWERP**PFEVKD**TEEE**DFHVDQ**VTTV**KVP**MMKRL**GMFNI**QHCK**KLSS**WVLL**MKYL**GNA*
*TAI**FFLP**D**EGKLQ**HLENEL**THDI**I**TK**FLE**NEDRR**SASL**HLPKLS**IT**GT**YDL**KSV**LGQ**L**GIT**K*
*VFS**NGAD**LSG**VTEE**APL**KL**SKAV**HKAV**LT**I**DEK**GTEA**AGAM**FLEA**IP**MS**I**P**PEV**KFN**KP**FV**F*
*LMIE**QNTK**SPL**FMG**KV**VNPTQ**K* (SEQ ID NO:52)

[225] In an embodiment each monomer of the dimeric protein has the sequence of SEQ ID No: 53. As shown below, AAT polypeptide portion of the fusion protein is underlined with Met351Glu and Met358Leu mutations indicated in boxes (SEQ ID No: 2). The IgG1-Fc polypeptide portion of the fusion protein is italicized (SEQ ID NO: 17), with deleted Gly236, and the mutations Met252Ile, Thr256Asp and Met428Leu mutations indicated in boxes.

EDPQGDAQAQKTDTSHHDDQDHPTFNKITPNLAEFAFSLYRQLAHQSNSTNIFFSPVSIATAFA
MLSLGTKADTHDEILEGLNFNLTEIPEAQIHEGFQELLRTLNQPDSQLQLTTGNGLFLSEGL
KLVDKFLEDVKKLYHSEAFTVNFGDTEEAKKQINDYVEKGTQGKIVDLVKELDRDTVFALVN
YIFFKGKWERPPFEVKDTEEEDFHVDQVTTVKVPMMKRLGMFNIQHCKKLSSWVLLMKYLGNA
TAIFFLPDEGKLQHLENELTHDIITKFLENEDRRSASLHLPKLSITGTYDLKSVLGQLGITK
VFSNGADLSGVTEEAPLKLSKAVHKAVLTIDEKGTEAAGAEFLEAIPLSIPPEVKFNKPFVF

LMIEQNTKSPLFMGKVVNPTQKGGGGDKTHTCPPCPAPEVAGPSVFLFPPKPKDTLIISRDP
EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEW
*ESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFC*SVLHEALHNHYTQKSLSL
 SPGK (SEQ ID NO: 53)

[226] In an embodiment each monomer of the dimeric protein has the sequence of SEQ ID No: 54. As shown below, AAT polypeptide portion of the fusion protein is underlined with Met351Glu and Met358Leu mutations indicated in boxes (SEQ ID No: 2). The IgG1-Fc polypeptide portion of the fusion protein is italicized (SEQ ID NO: 43), with Ser228Pro, Leu235Glu, Met252Ile, Thr256Asp and Met428Leu mutations indicated in boxes.

EDPQGDAQKTDTSHHQDHPTFNKITPNLAEFAFSLYRQLAHQSNSTNIFSPVSIATAFAMLSLGT
KADTHDEILEGLNFNLTETPEAQIHEGFQELLRTLNPDSQLQLTTGNGLFLSEGL
KLVDKFLEDVKKLYHSEAFTVNFGDTEEAQKQINDYVEKGTQGKIVDLVKELDRDTVFALVN
YIFFKGKWERPFEVKDTEEDFHVDQVTTVKVPMKRLGMFNIQHCKKLSSWVLLMKYLGNA
TAIFFLPDEGKLQHLLENELTHDIITKFLENEDRRSASLHLPKLSITGTYDLKSVLGQLGITK
VFSNGADLSGVTEEAPLKLSKAVHKAVLTIDEKGTEAAGAEFLEAIPLSIPPEVKFNKPFVF
LMIEQNTKSPLFMGKVVNPTQKESKYGPPCPAPEFEGGPSVFLFPPKPKDTLIISRDP
VTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYK
CKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWE
*SNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFC*SVLHEALHNHYTQKSLSL
 LGK (SEQ ID NO: 54)

[227] In an embodiment each monomer of the dimeric protein has the sequence of SEQ ID No: 55. As shown below, AAT polypeptide portion of the fusion protein is underlined, with AAT reactive loop sequence of SEQ ID NO: 51 with the Met351Leu mutation is shaded in black, and the Met358Leu mutation is shaded in grey and the IgG1-Fc polypeptide portion of the fusion protein is italicized (SEQ ID NO: 7).

EDPQGDAQKTDTSHHQDHPTFNKITPNLAEFAFSLYRQLAHQSNSTNIFSPVSIATAFAMLSLGT
KADTHDEILEGLNFNLTETPEAQIHEGFQELLRTLNPDSQLQLTTGNGLFLSEGLKLVDKFLEDVKK
LYHSEAFTVNFGDTEEAQKQINDYVEKGTQGKIVDLVKELDRDTVFALVNYIFFKGKWERPFEVKDTE
EEDFHVDQVTTVKVPMKRLGMFNIQHCKKLSSWVLLMKYLGNATAIFFLPDEGKLQHLLENELTHDII
TKFLENEDRRSASLHLPKLSITGTYDLKSVLGQLGITKVFSNGADLSGVTEEAPLKLSKAVHKAVLTI
DEKGTEAAGAEFLEAIPLSIPPEVKFNKPFVFLMIEQNTKSPLFMGKVVNPTQKEPKSCDKTHTCPPC
PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN
STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSL

*TCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH
NHYTQKSLSLSPGK* (SEQ ID NO: 55)

[228] In an embodiment each monomer of the dimeric protein has the sequence of SEQ ID No: 56. As shown below, AAT polypeptide portion of the fusion protein is underlined with the Met351Leu mutation is shaded in black, and the Met358Leu mutation is shaded in grey (SEQ ID No: 48): and the IgG4-Fc polypeptide portion of the fusion protein is italicized with mutations S228P, L235E, M252Y and M428L indicated in boxes, and a GS linker indicated in bold (SEQ ID NO: 40).

EDPQGDAQAQKTDTSHTDQDHPTFNKITPNLAFAFSLYRQLAHQSNSTNIFFSPVSIATAFAMLSLGTKADTHDEIL
EGLNFNLTIEPAQIHGEGFQELLRTLNPDSQLQLTTGNGLFLSEGLKLVDFLEDVKKLYHSEFTVNFSGDTEEA
KQINDYVEKGTQGGKIVDLVKELDRDTVFALVNYIFFKGKWERPFVKDTEEDFHVDQVTTVKVPMMKRLGMFNIQ
HCKKLSSWVLLMKYLGNAIAIFLPDEGKLQHLLENELTHDIITKFLNEDRRSASLHLPKLSITGTDLKSVLGQLGITK
VFSNGADLSGVTEEAPLKLSKAVHKAVLTIDEKGTEAAGA[FLEAIPLSIPPEVKFNKPFVFLMIEQNTKSPLFMGKV
VNPTQK**GS**ESKYGPPCP[CPAPEFEGGGSVFLFPPKPKDTL]YISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVH
NAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKN
QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSRLTVDKSRWQEGNVFSCSV[HEALHNHYT
QKSLSLSLGK (SEQ ID NO: 56)

[229] In some embodiments of the monomer of the dimeric protein of the disclosure, the IgG polypeptide portion of the monomer can be connected to the AAT polypeptide portion without a GS linker. In some embodiments, the IgG polypeptide portion of the monomer of the dimeric protein of the disclosure can be connected to the AAT polypeptide portion by covalent linkage.

[230] The monomers of the dimeric protein may be linked to each other by disulfide bridges. In particular, the pair of human immunoglobulin Fc polypeptide or polypeptide that is derived from an immunoglobulin Fc polypeptide are so linked to form a functional Fc domain.

OTHER EMBODIMENTS

[231] While the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

Examples

[232] General Methods

[233] Methods of assessing stability of an engineered dimeric protein

[234] a) Visual assessment

[235] Visible particles are suitably detected using the 2.9.20. European Pharmacopoeia Monograph (Particulate Contamination: Visible Particles). The apparatus required consists of a viewing station comprising:

- a matt black panel of appropriate size held in a vertical position
- a non-glare white panel of appropriate size held in a vertical position next to the black panel
- an adjustable lamp holder fitted with a suitable, shaded, white-light source and with a suitable light diffuser (a viewing illuminator containing two 13 W fluorescent tubes, each 525 mm in length, is suitable). The intensity of illumination at the viewing point is maintained between 2000 lux and 3750 lux.

[236] Any adherent labels are removed from the container and the outside washed and dried. The container is gently swirled or inverted, ensuring that air bubbles are not introduced, and observed for about 5 s in front of the white panel. The procedure is repeated in front of the black panel. The presence of any particles is recorded.

[237] The visual scores are ranked as follows:

Visual score 1: clear solution free of visible particles

Visual score 2: slight particle formation (up to ~20 very small particles)

Visual score 3: more significant precipitation (> 20 particles, including larger particles)

[238] Whilst the particles in samples with visual score 3 are clearly detectable on casual visual assessment under normal light, samples with visual score 1 and 2 generally appear as clear solutions on the same assessment. Samples with visual scores 1 and 2 are considered to be "Pass"; samples with visual score 3 are considered to be "Fail".

[239] (b) Size exclusion chromatography (SEC)**[240]** *Method 1*

[241] The amount of high molecular weight species is measured using a 300×7.8 mm TSK Gel G3000 SWXL (or equivalent) size-exclusion column. The mobile phase is 250 mM potassium chloride and 200 mM potassium phosphate buffer pH 6.2, with a flow rate of 0.5 ml/min, injection volume of 4 µl (corresponding to 200 microgram of protein) and detected at 280 nm. The run time is 30 min. The results are expressed as % high molecular species (HMWS), i.e. sum of all peak areas corresponding to aggregated protein over the sum of all protein-related peaks on the chromatogram.

[242] *Method 2*

[243] The amount of high molecular weight species is measured using a 300×7.8 mm TSK Gel G3000 SWXL (or equivalent) size-exclusion column. The mobile phase is 250 mM potassium chloride and 200 mM potassium phosphate buffer pH 6.2, with a flow rate of 0.5

ml/min, injection volume of 10 µl (corresponding to 500 microgram of protein) and detected at 280 nm. The run time is 30 min. The results are expressed as % high molecular species (HMWS), i.e. sum of all peak areas corresponding to aggregated protein over the sum of all protein-related peaks on the chromatogram.

[244] For both methods, the increase in % HMWS means the change observed in % HMWS at a given time-point compared with the % HMWS value at time zero (i.e. immediately before incubation at the storage temperature).

[245] (c) Sub visible particle assessment (SVP)

[246] The number of sub visible particles per container in a liquid sample is assessed using a HIAC 9703+ Liquid Particle Counter. A blank test and particle count set are used for system suitability. Samples are degassed for 10 minutes at 75 torr before measurement and tested undiluted. Results are reported as the average of three measurements of 5 mL each.

[247] Example 1 - Example formulations

[248] The following example formulation may be prepared:

[249] Example A:

Engineered dimeric protein of the invention 50 mg/ml

TRIS 3 mM

Trehalose 300 mM

Proline 100 mM

Polysorbate 20 0.1 mg/ml

Water for injection qs

pH adjusted to 7.3 using either hydrochloric acid or sodium hydroxide

Ionic strength 2.6 mM

[250] Example B:

Engineered dimeric protein of the invention 50 mg/ml

TRIS 3 mM

Trehalose 300 mM

Methionine 2 mM

Polysorbate 20 0.1 mg/ml

Water for injection qs

pH adjusted to 7.3 using either hydrochloric acid or sodium hydroxide

Ionic strength 2.6 mM

[251] Example C:

Engineered dimeric protein of the invention 50 mg/ml

TRIS 3 mM

Trehalose 300 mM

Proline	100 mM
Methionine	2 mM
Polysorbate 20	0.1 mg/ml
Water for injection	qs

pH adjusted to 7.3 using either hydrochloric acid or sodium hydroxide

Ionic strength	2.6 mM
----------------	--------

[252] Example D:

Engineered dimeric protein of the invention 50 mg/ml

TRIS	5 mM
Trehalose	300 mM
Proline	100 mM
Polysorbate 20	0.1 mg/ml
Water for injection	qs

pH adjusted to 7.3 using either hydrochloric acid or sodium hydroxide

Ionic strength	4.3 mM
----------------	--------

[253] Example E:

Engineered dimeric protein of the invention 50 mg/ml

TRIS	3 mM
Trehalose	300 mM
Proline	100 mM
Poloxamer 188	1 mg/ml
Water for injection	qs

pH adjusted to 7.3 using either hydrochloric acid or sodium hydroxide

Ionic strength	2.6 mM
----------------	--------

[254] Example F:

Engineered dimeric protein of the invention 50 mg/ml

TRIS	5 mM
Trehalose	300 mM
Proline	100 mM
Poloxamer 188	1 mg/ml
Water for injection	qs

pH adjusted to 7.3 using either hydrochloric acid or sodium hydroxide

Ionic strength	4.3 mM
----------------	--------

[255] Example G:

Engineered dimeric protein of the invention 50 mg/ml

TRIS	5 mM
------	------

Trehalose	150 mM
Sucrose	100 mM
Proline	100 mM
Polysorbate 20	0.1 mg/ml
Water for injection	qs
pH adjusted to 7.3 using either hydrochloric acid or sodium hydroxide	
Ionic strength	4.3 mM

[256] Example H:

Engineered dimeric protein of the invention 50 mg/ml

TRIS	5 mM
Trehalose	150 mM
Sucrose	100 mM
Proline	100 mM
Methionine	2 mM
Poloxamer 188	1 mg/ml
Water for injection	qs
pH adjusted to 7.3 using either hydrochloric acid or sodium hydroxide	
Ionic strength	4.3 mM

[257] Example I:

Engineered dimeric protein of the invention 50 mg/ml

TRIS	5 mM
Trehalose	150 mM
Sucrose	100 mM
Glycine	100 mM
Methionine	2 mM
Poloxamer 188	1 mg/ml
Water for injection	qs
pH adjusted to 7.3 using either hydrochloric acid or sodium hydroxide	
Ionic strength	4.3 mM

[258] Example J:

Engineered dimeric protein of the invention 50 mg/ml

TRIS	5 mM
Trehalose	150 mM
Sucrose	100 mM
Glycine	100 mM
Poloxamer 188	1 mg/ml

Water for injection qs
 pH adjusted to 7.3 using either hydrochloric acid or sodium hydroxide
 Ionic strength 4.3 mM

[259] Example K:

Engineered dimeric protein of the invention 50 mg/ml
 Sodium phosphate 5 mM
 Trehalose 150 mM
 Sucrose 100 mM
 Proline 100 mM
 Methionine 2 mM
 Polysorbate 20 0.1 mg/ml
 Water for injection qs
 pH adjusted to 7.3 using either hydrochloric acid or sodium hydroxide
 Ionic strength 11.1 mM

[260] Example L:

Engineered dimeric protein of the invention 50 mg/ml
 Sodium phosphate 5 mM
 Trehalose 150 mM
 Sucrose 100 mM
 Proline 100 mM
 Methionine 2 mM
 Poloxamer 188 1 mg/ml
 Water for injection qs
 pH adjusted to 7.3 using either hydrochloric acid or sodium hydroxide
 Ionic strength 11.1 mM

[261] The stability of the formulations can be determined using a visual assessment and SEC (see General Methods) following incubation at 40 °C for 2, 4 and 8 weeks.

[262] The stability of the formulations can be determined using a visual assessment and SEC (see General Methods) following incubation at 25 °C for 2, 4, 8, 12 and 26 weeks.

[263] The stability of the formulations can be determined using a visual assessment and SEC (see General Methods) following incubation at 2-8 °C for 2, 4, 8, 12 and 26 weeks.

[264] In the following Examples the engineered dimeric protein having SEQ ID NO: 56 as monomer sequence ("PROTEIN-1") was used.

[265] Example 2 – Effect of ionic strength on storage stability of PROTEIN-1

[266] The effect of ionic strength on the stability of PROTEIN-1 (50 mg/ml) was

investigated by comparing a charged tonicity modifier (sodium chloride, 150 mM) with an uncharged tonicity modifier (glycerol, 300 mM).

[267] All formulations contained polysorbate 20 (0.1 mg/mL) and either TRIS (2 mM) or sodium phosphate (2 mM) as buffer. Formulations containing TRIS were adjusted to pH 8.0 and those containing sodium phosphate were adjusted to pH 7.0. Table 1 summarises the formulations tested.

Table 1: Formulations of PROTEIN-1 tested. All formulations contained PROTEIN-1 (50 mg/ml) and polysorbate 20 (0.1mg/ml).

Formulation	TRIS (mM)	Sodium phosphate (mM)	Sodium chloride (mM)	Glycerol (mM)	pH	Ionic strength* (mM)
1-01	-	2	150	-	7.0	153.8
1-02	2	-	150	-	8.0	151.1
1-03	-	2	-	300	7.0	3.8
1-04	2	-	-	300	8.0	1.1

*Total ionic strength "I" as defined above

[268] All formulations were stored at 25 °C for 7 weeks. Stability of PROTEIN-1 was assessed by monitoring the rate of high molecular weight species formation using SEC (Method 1), and by visual assessment, as described in the General Methods.

[269] The rate of HMWS formation in formulations 1-01 to 1-04 is shown in Table 2, where it can be seen that the rate of HMWS formation was lowest in formulations of low ionic strength containing the uncharged tonicity modifier, glycerol (comparing formulation 1-01 with 1-03, and comparing formulation 1-02 with 1-04). The rate of HMWS formation was observed to be higher in formulations at pH 7.0 using sodium phosphate buffer, compared with the equivalent formulation at pH 8.0 using TRIS buffer (comparing formulation 1-01 with 1-02, and comparing formulation 1-03 with 1-04).

Table 2: Stability of PROTEIN-1 (50 mg/ml) at 25 °C for 7 weeks in formulations 1-01 to 1-04 assessed by SEC (Method 1).

Formulation	Increase in % HMWS
1-01	3.77
1-02	3.65
1-03	1.70
1-04	1.56

[270] Example 3 – Optimal pH for storage stability of PROTEIN-1

[271] The effect of pH on the stability of PROTEIN-1 (50 mg/ml) was investigated. All formulations contained polysorbate 20 (0.1 mg/ml), TRIS (1 mM) as buffer, and either trehalose (300 mM), a mixture of trehalose (150 mM) and mannitol (250 mM) as uncharged tonicity modifier. Some formulations contained methionine (2 mM). Table 3 summarises the formulations tested.

Table 3: Formulations of PROTEIN-1 tested. All formulations contained PROTEIN-1 (50 mg/mL)

Formulation	TRIS (mM)	Methionine (mM)	Trehalose (mM)	Mannitol (mM)	Polysorbate 20 (mg/mL)	pH	Ionic strength* (mM)
2-01	1	-	300	-	0.1	7.0	0.9
2-02	1	-	300	-	0.1	7.5	0.8
2-03	1	2	150	250	0.1	7.0	0.9
2-04	1	2	150	250	0.1	7.2	0.9
2-05	1	2	150	250	0.1	7.5	0.8
2-06	1	2	150	250	0.1	7.8	0.7

*Total ionic strength “I” as defined above

[272] Formulations were stored at 25 °C for 26 weeks, or at 2-8 °C for 26 weeks. Stability of PROTEIN-1 was assessed by monitoring the rate of high molecular weight species formation using SEC (Method 1), and by visual assessment, as described in the General Methods.

[273] The rate of HMWS formation in formulations 2-01 to 2-06 is shown in Table 4, where it can be seen that at 25 °C the rate of HMWS formation was lower in a formulation at pH 7.5 compared with a formulation at pH 7.0 at both 25 °C and 2-8 °C (comparing formulations 2-01 and 2-02 with trehalose as uncharged tonicity modifier). Comparing formulations 2-03 to 2-06 (with a mixture of trehalose and mannitol as uncharged tonicity modifier) it can be seen that although again the rate of HMWS formation was lower at pH 7.5 compared with pH 7.0 (for both 25 °C and 2-8 °C), the lowest rate of HMWS formation was observed at pH 7.2.

[274] In summary, pH 7.2-7.5 appears to be particularly suitable for preventing HMWS formation.

Table 4: Stability of PROTEIN-1 (50 mg/ml) at 25 °C and 2-8 °C for 26 weeks in formulations 2-01 to 2-06 assessed by SEC (Method 1).

Formulation	Increase in % HMWS	
	25°C	2-8°C
2-01	3.14	1.03
2-02	2.59	0.71
2-03	3.04	0.90
2-04	2.35	0.51
2-05	2.42	0.56
2-06	2.86	0.71

[275] Example 4 – Effect of buffer concentration on storage stability of PROTEIN-1

[276] The effect of buffer concentration on the stability of PROTEIN-1 (50 mg/ml) was investigated. All formulations contained polysorbate 20 (0.1 mg/ml). Table 5 summarises the formulations tested.

Table 5: Formulations of PROTEIN-1 tested. All formulations contained PROTEIN-1 (50 mg/ml) and polysorbate 20 (0.1 mg/ml)

Formulation	TRIS (mM)	Sodium phosphate (mM)	Methionine (mM)	Glycerol (mM)	Trehalose (mM)	Mannitol (mM)	pH	Ionic strength* (mM)
3-01	50	-	-	-	-	-	8.0	27.8
3-02	2	-	-	-	-	-	8.0	1.1
3-03	-	2	-	300	-	-	7.0	3.8
3-04	50	2	-	300	-	-	7.0	50.1
3-05	1	-	2	-	150	250	7.5	0.8
3-06	2	-	2	-	150	250	7.5	1.6
3-07	5	-	2	-	150	250	7.5	4

*Total ionic strength “I” as defined above

[277] Formulations were stored at 25 °C for 7 weeks and for 27 weeks, or at 2-8 °C for 27 weeks. Stability of PROTEIN-1 was assessed by monitoring the rate of high molecular weight species formation using SEC (Method 1), and by visual assessment, as described in the General Methods.

[278] The rate of HMWS formation in formulations 3-01 to 3-07 is shown in Table 6, where it can be seen that after 7 weeks at 25 °C the rate of HMWS formation was lower in a formulation containing 2 mM TRIS buffer compared with the corresponding formulation containing 50 mM TRIS buffer (comparing formulations 3-01 and 3-02, at pH 8). The same trend was observed at pH 7.0: the rate of HMWS was lower in a formulation containing no

TRIS buffer, compared with the corresponding formulation containing 50 mM TRIS buffer (comparing formulations 3-04 and 3-03, both of which contained glycerol as uncharged tonicity modifier, at pH 7.0). The same trend was observed after 27 weeks at both 25 °C and 2-8 °C, where reducing the concentration of TRIS buffer from 5 mM, to 2 mM and then to 1 mM led to a reduction in the rate of formation of HMWS (comparing formulations 3-05 to 3-07, which all contained a mixture of trehalose and mannitol as uncharged tonicity modifier, at pH 7.5).

[279] In summary, when using TRIS as buffer for the pH range 7.0-7.5, the concentration should be lower than 50 mM and suitably as low as possible to reduce the formation of HMWS.

Table 6: Stability of PROTEIN-1 (50 mg/ml) at 25 °C and 2-8 °C in formulations 3-01 to 3-07 assessed by SEC (Method 1).

Formulation	Increase in % HMWS		
	7 weeks	27 weeks	
	25°C	25°C	2-8°C
3-01	4.14		
3-02	3.32		
3-03	1.70		
3-04	2.84		
3-05		2.42	0.56
3-06		2.69	0.68
3-07		2.76	0.69

[280] Example 5 – Effect of uncharged tonicity modifier on storage stability of PROTEIN-1

[281] The effect of different uncharged tonicity modifiers on the stability of PROTEIN-1 (50 mg/ml) was investigated. All formulations contained polysorbate 20 (0.1 mg/ml). Table 7 summarizes the formulations tested.

Table 7: Formulations of PROTEIN-1 tested. All formulations contained PROTEIN-1 (50 mg/ml) and polysorbate 20 (0.1 mg/ml).

Formulation	TRIS (mM)	Glycerol (mM)	Trehalose (mM)	Sucrose (mM)	pH	Ionic strength* (mM)
4-01	2	300	-	-	7.0	1.9
4-02	2	-	300	-	7.0	1.9
4-03	2	-	-	300	7.0	1.9
4-04	1	-	300	-	7.5	0.8
4-05	1	-	200	-	7.5	0.8
4-06	1	-	-	300	7.5	0.8
4-07	1	-	-	200	7.5	0.8

*Total ionic strength "I" as defined above

[282] Formulations were stored at 25 °C for 12 weeks, at 25 °C for 26 weeks, 2-8 °C for 16 weeks or at 2-8 °C for 26 weeks. Stability of PROTEIN-1 was assessed by monitoring the rate of high molecular weight species formation using SEC (Method 1), and by visual assessment, as described in the General Methods.

[283] The rate of HMWS formation in formulations 4-01 to 4-07 is shown in Table 8, where it can be seen that after 12 weeks at 25 °C and after 16 weeks at 2-8 °C, comparing the use of glycerol, trehalose and sucrose as uncharged tonicity modifier, the rate of HMWS formation was lowest in the formulation containing trehalose (comparing formulations 4-01 to 4-03, at pH 7, with 2 mM TRIS buffer). The same was observed for longer storage periods of 26 weeks, comparing the use of trehalose and sucrose as uncharged tonicity modifier, the rate of HMWS was lower in the formulation containing trehalose (comparing formulations 4-04 to 4-07, at pH 7.5, with 1 mM TRIS buffer). Of the two trehalose concentrations tested (200 mM and 300 mM), a lower rate of HMWS formation was observed at the higher concentration of 300 mM (comparing formulations 4-04 and 4-05). However, in some cases, particularly if the dose volume of the composition is high, the concentration of trehalose may be limited due to pharmacologically acceptable limits, for example to around 150 mM. In such cases a mixture of trehalose with another uncharged tonicity modifier, for example sucrose, may be optimal.

[284] In summary, using trehalose as uncharged tonicity modifier provided the best stability profile for the concentrations and tonicity modifiers tested.

Table 8: Stability of PROTEIN-1 (50 mg/ml) at 25 °C and 2-8 °C in formulations 4-01 to 4-07 assessed by SEC (Method 1).

Formulation	Increase in % HMWS			
	25°C (12 weeks)	25°C (26 weeks)	2-8°C (16 weeks)	2-8°C (26 weeks)
4-01	2.90		3.19	
4-02	1.43		0.50	
4-03	1.65		0.85	
4-04		2.59		0.71
4-05		3.77		2.19
4-06		3.21		1.37
4-07		4.27		2.93

[285] Example 6 – Effect of neutral amino acids on storage stability of PROTEIN-1

[286] The effect of different neutral amino acids on the stability of PROTEIN-1 (50 mg/ml) was investigated. All formulations contained polysorbate 20 (0.1 mg/ml), TRIS buffer (2 mM), and glycerol (300 mM) as uncharged tonicity modifier. Table 9 summarises the formulations tested.

Table 9: Formulations of PROTEIN-1 tested. All formulations contained PROTEIN-1 (50 mg/mL) and polysorbate 20 (0.1 mg/ml).

Formulation	TRIS (mM)	Glycerol (mM)	Glycine (mM)	Proline (mM)	pH	Ionic strength* (mM)
5-01	2	300	100	-	7.0	1.9
5-02	2	300	300	-	7.0	1.9
5-03	2	300	-	100	7.0	1.9
5-04	2	300	-	300	7.0	1.9
5-05	2	300	-	500	7.0	1.9
5-06	2	300	-	-	7.0	1.9

*Total ionic strength “I” as defined above

[287] Formulations were stored at 25 °C for 16 weeks. Stability of PROTEIN-1 was assessed by monitoring the rate of high molecular weight species formation using SEC (Method 1), and by visual assessment, as described in the General Methods.

[288] The rate of HMWS formation in formulations 5-01 to 5-06 is shown in Table 10, where it can be seen that after 16 weeks at 25 °C, the addition of both glycine (at 300 mM) and proline (at all concentrations tested) resulted in a lower rate of HMWS formation (comparing formulations 5-01 to 5-05 with control formulation 5-06). Comparing glycine and

proline directly, at a given concentration of neutral amino acid, the rate of HMWS formation was lower in the formulations containing proline (comparing formulation 5-01 with formulation 5-03, and comparing formulation 5-02 with formulation 5-04). Of the three proline concentrations tested (100 mM, 200 mM and 500 mM), the lowest rate of HMWS formation was observed at the highest concentration of 500 mM (comparing formulations 5-05 and 5-05). However, in practice the concentration of proline used in a commercial therapeutic formulation would ideally be lower (e.g. around 100-150 mM) due to osmolarity limitations.

[289] In summary, the addition of a neutral amino acid (e.g. proline or glycine, particularly proline) resulted in a more stable formulation.

Table 10: Stability of PROTEIN-1 (50 mg/ml) at 25 °C for 16 weeks in formulations 5-01 to 5-06 assessed by SEC (Method 1).

Formulation	Increase in % HMWS
5-01	3.96
5-02	3.18
5-03	3.57
5-04	2.88
5-05	2.40
5-06	3.82

[290] Example 7 – Effect of methionine in combination with another neutral amino acid, on storage stability of PROTEIN-1

[291] The effect of methionine in combination with either of neutral amino acids glycine or proline, on the stability of PROTEIN-1 (50 mg/ml) was investigated. All formulations contained polysorbate 20 (0.1 mg/ml), TRIS buffer (2 mM or 1 mM), and glycerol (300 mM) or trehalose (300 mM) as uncharged tonicity modifier. Table 11 summarizes the formulations tested.

Table 11: Formulations of PROTEIN-1 tested. All formulations contained PROTEIN-1 (50 mg/ml) and polysorbate 20 (0.1 mg/ml).

Formulation	TRIS (mM)	Methionine (mM)	Glycerol (mM)	Glycine (mM)	Proline (mM)	Trehalose (mM)	pH	Ionic strength* (mM)
6-01	2	-	300	300	-	-	7.0	1.9
6-02	2	10	300	300	-	-	7.0	1.9
6-03	1	-	-	-	200	300	7.5	0.8
6-04	1	2	-	-	200	300	7.5	0.8

*Total ionic strength “I” as defined above

[292] Formulations were stored at 25 °C for 16 weeks, at 25 °C for 26 weeks, or at 2-8 °C for 26 weeks. Stability of PROTEIN-1 was assessed by monitoring the rate of high molecular weight species formation using SEC (Method 1), and by visual assessment, as described in the General Methods.

[293] The rate of HMWS formation in formulations 6-01 to 6-04 is shown in Table 12, where it can be seen that after 16 weeks at 25 °C, the addition of methionine to a formulation containing glycine led to a lower rate of formation of HMWS (comparing formulations 6-01 and 6-02). The addition of methionine to a formulation containing proline also led to a lower rate of formation of HMWS after 26 weeks at 25 °C or after 26 weeks at 2-8 °C (comparing formulations 6-03 and 6-04).

Table 12: Stability of PROTEIN-1 (50 mg/ml) at 25 °C in formulations 6-01 to 6-04 assessed by SEC (Method 1).

Formulation	Increase in % HMWS		
	25°C (16 weeks)	25°C (26 weeks)	2-8°C (26 weeks)
6-01	3.18		
6-02	2.62		
6-03		2.15	0.15
6-04		1.87	0.07

[294] Example 8 – Storage stability testing of formulation of PROTEIN-1 with poloxamer surfactant

[295] The effect of poloxamer surfactant on the stability of PROTEIN-1 (50 mg/ml) was investigated. The batch of PROTEIN-1 used in this example was a different batch to that used in Examples 2-7. Table 13 summarises the formulation tested.

Table 13: Formulations of PROTEIN-1 tested. The formulation contained PROTEIN-1 (50 mg/ml).

Formulation	TRIS (mM)	Methionine (mM)	Trehalose (mM)	Sucrose (mM)	Proline (mM)	Poloxamer 188 (mg/ml)	pH	Ionic strength* (mM)
7-01	2	2	150	100	100	1.0	7.5	1.6

*Total ionic strength "I" as defined above

[296] The formulation was stored at 25 °C and at 2-8 °C for 6 months, 9 months, 12 months and 24 months. Stability of PROTEIN-1 was assessed by monitoring the rate of high molecular weight species formation using SEC (Method 1), and by visual assessment, as described in the General Methods.

[297] The formulation had a low rate of HMWS formation under the storage conditions as can be seen from Tables 14A and 14B.

[298] As shown in Tables 15A and 15B, the formulation tested passed the visual test following storage at 25 °C and at 2-8 °C.

Table 14A: Stability of PROTEIN-1 (50 mg/ml) at 2-8 °C in formulation 7-01 assessed by SEC (Method 1).

Formulation	Increase in %HMWS at 2-8°C				
	6 months	9 months	12 months	18 months	24 months
7-01	1.08	1.71	2.51	4.03	5.61

Table 14B: Stability of PROTEIN-1 (50 mg/ml) at 25 °C in formulation 7-01 assessed by SEC (Method 1).

Formulation	Increase in %HMWS at 25°C				
	6 months	9 months	12 months	18 months	24 months
7-01	3.36	5.06	7.19	11.10	15.49

Table 15A: Stability of PROTEIN-1 (50 mg/ml) at 2-8 °C in formulation 7-01 assessed using visual assessment.

Formulation	Visual score at 2-8°C				
	6 months	9 months	12 months	18 months	24 months
7-01	1	1	1	1	1

Table 15B: Stability of PROTEIN-1 (50 mg/ml) at 25 °C in formulation 7-01 assessed using visual assessment.

Formulation	Visual score at 25°C				
	6 months	9 months	12 months	18 months	24 months
7-01	1	1	1	1	1

[299] Example 9 – Sub visible particle size limit assessment for formulation of PROTEIN-1

[300] The stability of the formulation of PROTEIN-1 set out in Table 16A was assessed by visual assessment, and by determining the number of sub visible particles (SVP) after storage for 6 months at 25 °C, both as described in the General Methods.

Table 16A: Formulation of PROTEIN-1 (50 mg/ml) tested.

Formulation	TRIS (mM)	Methionine (mM)	Trehalose (mM)	Sucrose (mM)	Prolin e (mM)	Poloxamer 188 (mg/ml)	pH	Ionic strength* (mM)
9-01	5	2	150	100	100	1.0	7.3	4.3

*Total ionic strength “I” as defined above

[301] Following storage for 6 months at 25 °C, Formulation 9-01 was practically free of visible particles. The number of sub visible particles is shown in Table 16B.

Table 16B: Number of sub visible particles following storage of Formulation 9-01 for 6 months at 25 °C.

Formulation	Number of sub visible particles per container	
	≥ 10 µm	≥ 25 µm
9-01	67	0

[302] USP <788> “Particulate matter in injections” 11 (harmonized with Ph. Eur. 2.9.19) requires preparations of less than 100 mL to contain no more than 6000 particles ≥10 µm per container and no more than 600 particles ≥25 µm per container as determined by light obscuration (such as the HIAC method in the General Methods). As such, following long term storage Formulation 9-01 is well below the necessary upper limits for sub visible particles, indicating excellent storage stability.

[303] Example 10 – Design of experiment (DOE) study assessing concentration of formulation components on stability of PROTEIN-1

[304] The effect of varying concentrations of protein, buffer and poloxamer surfactant on

the stability of PROTEIN-1 was assessed by monitoring the rate of formation of high molecular weight species in the formulations using SEC (Method 2), as described in the General Methods. The rate of HMWS formation in the various formulations after 12 months at 5 °C is shown in Table 17.

Table 17: Stability of PROTEIN-1 at 5 °C for 12 months assessed by SEC (Method 2).

Formulation	PROTEIN-1 (mg/mL)	Tris (mM)	pH	Poloxamer 188 (%)	Increase in % HMWS @ 12 m
RF08	58	10	7.7	0.03	3.3
RF01	58	10	7.7	0.17	3.3
RF15	58	2	7.7	0.03	2.6
RF16	58	2	7.7	0.17	2.4
RF02	42	10	7.7	0.03	2.4
RF11	42	10	7.7	0.17	2.4
RF09	42	2	7.7	0.03	1.7
RF05	42	2	7.7	0.17	1.7

[305] All formulations tested exhibited good storage stability. Comparing Formulations RF08 with RF02, RF01 with RF11, RF15 with RF09, and RF16 with RF05, it can be seen that lowering the protein concentration results in a slight improvement in stability. Comparing Formulations RF08 and RF01 with RF15 and RF16, and comparing Formulations RF02 and RF11 with RF09 and RF05, it can be seen that a lower buffer (TRIS) concentration results in a slight improvement in stability, although the higher buffer (TRIS) concentration of 10 mM still provides a formulation with good stability. Finally, the effect on storage stability of raising the poloxamer concentration from 0.03% to 0.17% was minimal.

[306] Comparative Example 11 – Effect of buffer concentration, charge of tonicity modifier and a neutral amino acid on storage stability of an immunoglobulin G1 (IgG1) at 30 °C

[307] The effect of buffer concentration and charge of the tonicity modifier on stability of an IgG1 (100 mg/ml) was investigated. Citrate buffer was tested. Sodium chloride (150 mM) was used as a charged tonicity modifier and glycerol (300 mM) was used as an uncharged tonicity modifier. The effect of proline and glycine (50 mM) on stability of the IgG1 was also investigated in the presence of 1 mM buffer and glycerol (300 mM). All formulations tested contained polysorbate 80 (0.2 mg/ml) and were adjusted to pH 6.0. Table 18 summarizes the formulations tested. All formulations were stressed at 30 °C for 8 weeks. Stability of the IgG1 was followed by monitoring the rate of high molecular weight species formation using SEC (Method 1).

Table 18: Formulations of IgG1 tested. All formulations contained IgG1 (100 mg/ml) and polysorbate 80 (0.2 mg/ml) and were adjusted to pH 6.0.

Formulation	Citric acid (mM)	Sodium chloride (mM)	Glycerol (mM)	Proline (mM)	Glycine (mM)	Ionic strength* (mM)
8-01	1	150	-	-	-	153.8
8-02	5	150	-	-	-	168.7
8-03	20	150	-	-	-	224.8
8-04	1	-	300	-	-	3.8
8-05	5	-	300	-	-	18.7
8-06	20	-	300	-	-	74.8
8-07	1	-	300	50	-	3.8
8-08	1	-	300	-	50	3.8

*Total ionic strength "I" as defined above

[308] All formulations tested passed the visual test following storage at 30 °C. The rate of HMWS formation in formulations 8-01 to 8-08 following storage at 30 °C is shown in Table 19. The rate of HMWS formation decreased with increasing buffer concentration both in the presence of sodium chloride and in the presence of glycerol (comparing formulations 8-01 to 8-03, and comparing formulations 8-04 to 8-06). There was a slight trend for higher stability at higher ionic strength of the formulation when the citric acid concentration was low (1 or 5 mM) (comparing formulation 8-01 with formulation 8-04 and comparing formulation 8-02 with formulation 8-05). This order was reversed when the citric acid concentration was high (20 mM) (comparing formulation 8-03 with formulation 8-06) although in this instance the ionic strength of both formulations was above 70 mM. The presence of a neutral amino acid (proline or glycine) resulted in a very slight increase in the rate of HMWS formation (comparing formulation 8-04 with formulations 8-07 and 8-08).

Table 19: Stability of IgG1 (100 mg/ml) at 30 °C in formulations 8-01 to 8-08 assessed by SEC (Method 1).

Formulation	Increase in % HMWS following incubation at 30 °C for 8 weeks
8-01	6.28
8-02	5.15
8-03	4.41
8-04	6.58

Formulation	Increase in % HMWS following incubation at 30 °C for 8 weeks
8-05	5.48
8-06	4.27
8-07	6.67
8-08	6.68

[309] Summary of the Examples

[310] The data of Examples 2-10 shows that compositions of the engineered dimeric protein of the invention as defined herein such as PROTEIN-1 are stable when formulated at low ionic strength with a neutral amino acid. The ionic strength of a composition is suitably kept low by using a low buffer concentration (or by not using any buffer) and by using an uncharged tonicity modifier instead of a charged tonicity modifier.

[311] When these data are compared to Comparative Example 11, it can be seen that this behavior is quite different to the behavior exhibited by the tested 4-chain antibody (type IgG1). The latter was found to be more stable at higher buffer concentrations and, in some cases, at higher ionic strength and was also found to be destabilized in the presence of a neutral amino acid.

[312] The present invention combines composition features that, without being limited by theory, are believed to work in concert to screen unnatural hydrophobic patches as well as minimizing the rate of proton exchange at unnaturally exposed sites of instability, resulting in stability of the engineered dimeric protein of the invention such as PROTEIN-1.

[313] Throughout the specification and the claims which follow, unless the context requires otherwise, the word 'comprise', and variations such as 'comprises' and 'comprising', will be understood to imply the inclusion of a stated integer, step, group of integers or group of steps but not to the exclusion of any other integer, step, group of integers or group of steps.

[314] All patents, patent applications and references mentioned throughout the specification of the present invention are herein incorporated in their entirety by reference.

[315] The invention embraces all combinations of preferred and more preferred groups and suitable and more suitable groups and embodiments of groups recited above.

Claims

1. An aqueous solution composition of pH in the range 6.0 to 8.0 comprising:
 - an engineered dimeric protein wherein each monomer of the dimeric protein comprises at least one human serpin polypeptide operably linked to a human immunoglobulin Fc polypeptide or a polypeptide that is derived from an immunoglobulin Fc polypeptide;
 - optionally one or more buffers being substances having at least one ionisable group with a pK_a in the range 4.0 to 10.0 and which pK_a is within 2 pH units of the pH of the composition;
 - a neutral amino acid; and
 - an uncharged tonicity modifier;wherein the buffers are present in the composition at a total concentration of 0-10 mM; and wherein the total ionic strength of the composition excluding the contribution of the engineered dimeric protein is less than 30 mM.
2. An aqueous solution composition according to claim 1, wherein the human serpin polypeptide is a human alpha-1 antitrypsin (AAT) polypeptide or is derived from a human AAT polypeptide.
3. An aqueous solution composition according to claim 1 or claim 2, wherein each monomer of the dimeric protein comprises one human serpin polypeptide.
4. An aqueous solution composition according to claim 2 or 3, wherein the human serpin polypeptide has the sequence of SEQ ID NO: 1 or 2.
5. An aqueous solution composition according to any one of claims 1 to 4, wherein the human immunoglobulin Fc polypeptide or a polypeptide that is derived from an immunoglobulin Fc polypeptide is a modified human IgG4 Fc polypeptide.
6. An aqueous solution composition according to claim 5, wherein the human immunoglobulin Fc polypeptide or a polypeptide that is derived from an immunoglobulin Fc polypeptide is a modified human IgG4 Fc polypeptide and has the sequence of any one of SEQ ID NOs: 28-43.
7. An aqueous solution composition according to any one of claims 1 to 6, wherein each monomer of the dimeric protein has the sequence of SEQ ID No: 56.

8. An aqueous solution composition according to any one of claims 1 to 7, wherein the protein is present at a concentration of 1-400 mg/ml e.g. 10-200 mg/ml e.g. 20-100 mg/ml e.g. 30-60 mg/ml e.g. about 35 mg/ml or about 50 mg/ml.
9. An aqueous solution composition according to any one of claims 1 to 8, wherein buffers are present at a total concentration of 0.1-10 mM, such as 0.5-10 mM such as 1-10 mM, such as 1-8 mM, such as 1-6 mM, such as 2-6 mM, such as 2-5 mM e.g. 3-5 mM.
10. An aqueous solution composition according to any one of claims 1 to 8, which is substantially free of buffers.
11. An aqueous solution composition according to any one of claims 1 to 9, wherein the buffer comprises ionisable groups with pK_a within 1 unit of the pH of the composition.
12. An aqueous solution composition according to any one of claims 1 to 9 and 11, wherein the buffer or buffers is/are selected from the group consisting of citrate, histidine, maleate, sulphite, aspartame, aspartate, glutamate, tartrate, adenine, succinate, ascorbate, benzoate, phenylacetate, gallate, cytosine, *p*-aminobenzoic acid, sorbate, acetate, propionate, alginate, urate, 2-(*N*-morpholino)ethanesulphonic acid, bicarbonate, bis(2-hydroxyethyl)iminotris(hydroxymethyl)methane, *N*-(2-acetamido)-2-iminodiacetic acid, 2-[(2-amino-2-oxoethyl)amino]ethanesulphonic acid, piperazine, *N,N'*-bis(2-ethanesulphonic acid), phosphate, *N,N*-bis(2-hydroxyethyl)-2-aminoethanesulphonic acid, 3-[*N,N*-bis(2-hydroxyethyl)amino]-2-hydroxypropanesulphonic acid, triethanolamine, piperazine-*N,N'*-bis(2-hydroxypropanesulphonic acid), tris(hydroxymethyl)aminomethane (TRIS), *N*-tris(hydroxymethyl)glycine and *N*-tris(hydroxymethyl)methyl-3-aminopropanesulphonic acid, and salts thereof, and combinations thereof.
13. An aqueous solution composition according to claim 12, wherein the buffer is selected from the group consisting of citrate, histidine, maleate, tartrate, benzoate, acetate, bicarbonate, phosphate and tris(hydroxymethyl)aminomethane (TRIS), for example, selected from phosphate and TRIS.
14. An aqueous solution composition according to any one of claims 1 to 13, wherein the uncharged tonicity modifier is selected from the group consisting of polyols, sugars (e.g. monosaccharides and disaccharides) and sugar alcohols.
15. An aqueous solution composition according to claim 14, wherein the uncharged tonicity modifier is selected from the group consisting of glycerol, 1,2-propanediol, mannitol, sorbitol, glucose, sucrose, trehalose, PEG300 and PEG400, and in particular is selected from glycerol, mannitol, sucrose and trehalose.

16. An aqueous solution composition according to claim 14 or claim 15, comprising a disaccharide as an uncharged tonicity modifier.
17. An aqueous solution composition according to claim 16, comprising sucrose and/or trehalose as the uncharged tonicity modifier, in particular trehalose.
18. An aqueous solution composition according to any one of claims 1 to 17, wherein the total concentration of the uncharged tonicity modifier, or combination of more than one tonicity modifier, is 50-1000 mM, such as 200-600 mM, 200-500 mM or wherein the total concentration of the uncharged tonicity modifier, or combination of more than one tonicity modifier, is 50-500 mM, such as 100-400 mM, 150-350 mM, 200-300 mM or about 250 mM.
19. An aqueous solution composition according to any one of claims 1 to 17, wherein the osmolarity of the composition is 200-500 mOsm/L e.g. about 300 mOsm/L or wherein the osmolarity of the composition is 300-500 mOsm/L e.g. about 400-460 mOsm/L.
20. An aqueous solution composition according to any one of claims 1 to 19, comprising a neutral amino acid selected from glycine, methionine, proline, alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, tryptophan, serine, threonine, asparagine and glutamine.
21. An aqueous solution composition according to claim 20, wherein the neutral amino acid is selected from glycine, methionine and proline.
22. An aqueous solution composition according to claim 20, comprising proline as a neutral amino acid.
23. An aqueous solution composition according to claim 20, comprising glycine as a neutral amino acid.
24. An aqueous solution composition according to claim 20, comprising proline and methionine as neutral amino acids.
25. An aqueous solution composition according to claim 20, comprising glycine and methionine as neutral amino acids.
26. An aqueous solution composition according to any one of claims 1 to 25, wherein the total concentration of the one or more neutral amino acids in the composition is 20 to 600 mM, such as 20 to 500 mM, such as 20 to 400 mM, such as 20 to 300 mM e.g. 50 to 300 mM.
27. An aqueous solution composition according to any one of claims 1 to 25, wherein the total concentration of the one or more neutral amino acids in the composition is 50 to 200 mM, 100 to 200 mM or 100 to 150 mM.

28. An aqueous solution composition according to any one of claims 1 to 27, wherein the total ionic strength of the composition excluding the contribution of the engineered dimeric protein is less than 20 mM.
29. An aqueous solution composition according to claim 28, wherein the total ionic strength of the composition excluding the contribution of the engineered dimeric protein is less than 10 mM.
30. An aqueous solution composition according to any one of claims 1 to 29, wherein the pH is between 6.8 and 7.8, for example between 7.0 and 7.8, between 7.1 and 7.6, between 7.1 and 7.5, between 7.2 and 7.5, between 7.1 and 7.4, between 7.2 and 7.3; or is about 7.2 or about 7.3.
31. An aqueous solution composition according to any one of claims 1 to 30, which comprises a non-ionic surfactant.
32. An aqueous solution composition according to claim 31, wherein the non-ionic surfactant is selected from the group consisting of an alkyl glycoside, a polysorbate, an alkyl ether of polyethylene glycol, a block copolymer of polyethylene glycol and polypropylene glycol (poloxamer), and an alkylphenyl ether of polyethylene glycol.
33. An aqueous solution composition according to claim 32, wherein the non-ionic surfactant is a polysorbate such as polysorbate 20 or polysorbate 80.
34. An aqueous solution composition according to claim 32, wherein the non-ionic surfactant is a block copolymer of polyethylene glycol and polypropylene glycol (poloxamer), such as poloxamer 188.
35. An aqueous solution composition according to any one of claims 31 to 34, wherein the non-ionic surfactant is present at a concentration of 10-2000 µg/ml, such as 50-1000 µg/ml, e.g. 100-500 µg/ml e.g. about 200 µg/ml or wherein the non-ionic surfactant is present at a concentration of 250-1500 µg/ml e.g. 750-1250 µg/ml e.g. about 1000 µg/ml.
36. An aqueous solution composition according to any one of claims 1 to 35, which comprises a preservative such as a phenolic or benzylic preservative.
37. An aqueous solution composition according to claim 36, wherein the phenolic or benzylic preservative is selected from the group consisting of phenol, m-cresol, chlorocresol, benzyl alcohol, propyl paraben and methyl paraben.
38. An aqueous solution composition according to claim 36 or claim 37, wherein the preservative is present at a concentration of 10-100 mM, such as 20-80 mM e.g. 25-50 mM.

39. An aqueous solution composition according to any one of claims 1 to 38, which is a composition for use in therapy.
40. An aqueous solution composition according to any one of claims 1 to 38, which is a pharmaceutical composition.
41. A method of treating or alleviating a symptom of a disease or disorder associated with aberrant serine protease expression or activity in a subject in need thereof, the method comprising administering an aqueous solution composition according to any one of claims 1 to 40.
42. A method of treating or alleviating inflammation or a symptom of an inflammatory disease or disorder while reducing the risk of infection, in a subject in need thereof, the method comprising administering to said subject an aqueous solution composition according to any one of claims 1 to 40.
43. A method of reducing the risk of infection in a subject in need thereof, the method comprising administering to said subject an aqueous solution composition according to any one of claims 1 to 40.
44. A method of treating or alleviating a symptom of AAT deficiency in a subject in need thereof, the method comprising administering to said subject an aqueous solution composition according to any one of claims 1 to 40, wherein the human serpin polypeptide is a human alpha- 1 antitrypsin (AAT) polypeptide or is derived from a human AAT polypeptide.
45. An aqueous solution composition according to any one of claims 1 to 40, for use in a method of treating or alleviating a symptom of a disease or disorder associated with aberrant serine protease expression or activity in a subject in need thereof.
46. An aqueous solution composition according to any one of claims 1 to 40, for use in a method of treating or alleviating inflammation or a symptom of an inflammatory disease or disorder while reducing the risk of infection, in a subject in need thereof.
47. An aqueous solution composition according to any one of claims 1 to 40, for use in a method of reducing the risk of infection in a subject in need thereof.
48. An aqueous solution composition according to any one of claims 1 to 40, for use in a method of treating or alleviating a symptom of AAT deficiency in a subject in need thereof, wherein the human serpin polypeptide is a human alpha- 1 antitrypsin (AAT) polypeptide or is derived from a human AAT polypeptide.

49. Use of an aqueous solution composition according to any one of claims 1 to 40, for the manufacture of a medicament for treating or alleviating a symptom of a disease or disorder associated with aberrant serine protease expression or activity in a subject in need thereof.
50. Use of an aqueous solution composition according to any one of claims 1 to 40, for the manufacture of a medicament for treating or alleviating inflammation or a symptom of an inflammatory disease or disorder while reducing the risk of infection, in a subject in need thereof.
51. Use of an aqueous solution composition according to any one of claims 1 to 40, for the manufacture of a medicament for reducing the risk of infection in a subject in need thereof.
52. Use of an aqueous solution composition according to any one of claims 1 to 40, for the manufacture of a medicament for treating or alleviating a symptom of AAT deficiency in a subject in need thereof, wherein the human serpin polypeptide is a human alpha- 1 antitrypsin (AAT) polypeptide or is derived from a human AAT polypeptide.
53. The method, aqueous solution composition for use, or use, according to any one of claims 42, 46 and 50, wherein the inflammatory disease or disorder is selected from the following: alpha- 1 antitrypsin (AAT) deficiency, emphysema, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), allergic asthma, cystic fibrosis, cancers of the lung, ischemia-reperfusion injury, ischemia/reperfusion injury following cardiac transplantation, myocardial infarction, rheumatoid arthritis, septic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, type I and/or type II diabetes, pneumonia, sepsis, graft versus host disease (GVHD), wound healing, systemic lupus erythematosus, and multiple sclerosis.
54. The method, aqueous solution composition for use, or use, according to any one of claims 42, 43, 46, 47, 50 and 51, wherein the infection is selected from bacterial infections, fungal infections and viral infections.
55. The method, aqueous solution composition for use, or use, according to any one of claims 41 to 54, wherein the subject is a human.

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2022/016864

A. CLASSIFICATION OF SUBJECT MATTER		
INV.	A61K9/08	A61P37/06
	A61P37/02	A61K47/18
		A61K47/36
ADD.		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
A61K A61P C07K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
EPO-Internal, BIOSIS, EMBASE, WPI Data, Sequence Search		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 2010/286066 A1 (DURRANI MANZER [US] ET AL) 11 November 2010 (2010-11-11) claims 1,11-13,17 -----	1-55
Y	WO 2019/122935 A1 (ARECOR LTD [GB]) 27 June 2019 (2019-06-27) claims 1,2,15,23,26,30 -----	1-55
X	WO 2013/003641 A2 (INHIBRX LLC [US]; ECKELMAN BRENDAN P [US] ET AL.) 3 January 2013 (2013-01-03) claim 1; sequences 18,34 -----	1-55
X	WO 2015/191892 A2 (BETH ISRAEL HOSPITAL [US]) 17 December 2015 (2015-12-17) claim 1; sequences 12,16,18 ----- -/-	1-55
☒ Further documents are listed in the continuation of Box C. ☒ See patent family annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance;; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance;; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
13 May 2022		25/05/2022
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016		Authorized officer Griesinger, Irina

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2022/016864

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2008/084237 A2 (ARECOR LTD [GB]; JEZEK JAN [GB]) 17 July 2008 (2008-07-17) abstract -----	1-55
Y	WO 2006/138181 A2 (AMGEN INC [US]; GOKARN YATIN R [US] ET AL.) 28 December 2006 (2006-12-28) claims 7,10,18,22 -----	1-55
A	MARIELE GATTO ET AL: "Serpins, Immunity and Autoimmunity: Old Molecules, New Functions", CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, vol. 45, no. 2, 17 January 2013 (2013-01-17), pages 267-280, XP055093192, ISSN: 1080-0549, DOI: 10.1007/s12016-013-8353-3 take home message on page 277 -----	1-55
A	GODDARD ET AL: "Therapeutic proteins - a pharmaceutical perspective", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, AMSTERDAM , NL, vol. 6, no. 2, 1 March 1991 (1991-03-01), pages 103-131, XP023764145, ISSN: 0169-409X, DOI: 10.1016/0169-409X(91)90036-C [retrieved on 1991-03-01] -----	1-55

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2022/016864

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
 - a. ☒ forming part of the international application as filed:
 - ☒ in the form of an Annex C/ST.25 text file.
 - ☐ on paper or in the form of an image file.
 - b. ☐ furnished together with the international application under PCT Rule 13ter.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
 - c. ☐ furnished subsequent to the international filing date for the purposes of international search only:
 - ☐ in the form of an Annex C/ST.25 text file (Rule 13ter.1(a)).
 - ☐ on paper or in the form of an image file (Rule 13ter.1(b) and Administrative Instructions, Section 713).
2. ☐ In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2022/016864

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2010286066 A1	11-11-2010	AT 530165 T	15-11-2011
		AU 2004290587 A1	02-06-2005
		CA 2545855 A1	02-06-2005
		DK 1684719 T3	30-01-2012
		EP 1684719 A2	02-08-2006
		ES 2375706 T3	05-03-2012
		JP 2007511539 A	10-05-2007
		PL 1684719 T3	30-11-2012
		PT 1684719 E	03-02-2012
		SI 1684719 T1	31-07-2012
		US 2008312136 A1	18-12-2008
		US 2010286066 A1	11-11-2010
		WO 2005048985 A2	02-06-2005
WO 2019122935 A1	27-06-2019	CN 111511351 A	07-08-2020
		EP 3727455 A1	28-10-2020
		KR 20200102432 A	31-08-2020
		US 2021085751 A1	25-03-2021
		WO 2019122935 A1	27-06-2019
WO 2013003641 A2	03-01-2013	AU 2012275287 A1	16-01-2014
		AU 2017279724 A1	25-01-2018
		AU 2019202904 A1	16-05-2019
		AU 2021202131 A1	06-05-2021
		BR 112013033799 A2	14-02-2017
		CA 2839619 A1	03-01-2013
		CA 3132298 A1	03-01-2013
		CN 103917563 A	09-07-2014
		CN 110066340 A	30-07-2019
		CN 110551223 A	10-12-2019
		DK 2726092 T3	30-09-2019
		EP 2726092 A2	07-05-2014
		EP 3569243 A1	20-11-2019
		ES 2746052 T3	04-03-2020
		HR P20191652 T1	13-12-2019
		HU E046156 T2	28-02-2020
		IL 230209 A	31-08-2020
		JP 6674604 B2	01-04-2020
		JP 2014523900 A	18-09-2014
		JP 2018008956 A	18-01-2018
		JP 2020078325 A	28-05-2020
		KR 20140054000 A	08-05-2014
		KR 20200027041 A	11-03-2020
		KR 20210032558 A	24-03-2021
		KR 20220003656 A	10-01-2022
		LT 2726092 T	10-10-2019
		ME 03473 B	20-01-2020
		MX 356517 B	01-06-2018
		NZ 619023 A	31-07-2015
		PL 2726092 T3	29-11-2019
		PT 2726092 T	08-10-2019
		RU 2727452 C1	21-07-2020
		RU 2728861 C1	31-07-2020
		RU 2014102583 A	10-08-2015
		RU 2017145308 A	18-02-2019
		RU 2020124172 A	21-01-2022
		SG 10201601621P A	28-04-2016
		SG 10201811256Q A	30-01-2019

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2022/016864

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		SI 2726092 T1	29-11-2019
		US 2013011398 A1	10-01-2013
		US 2013330769 A1	12-12-2013
		US 2015147325 A1	28-05-2015
		US 2018179264 A1	28-06-2018
		US 2020102371 A1	02-04-2020
		US 2021002352 A1	07-01-2021
		US 2021024613 A1	28-01-2021
		WO 2013003641 A2	03-01-2013
WO 2015191892 A2	17-12-2015	EP 3155117 A2	19-04-2017
		US 2017190762 A1	06-07-2017
		US 2019276516 A1	12-09-2019
		WO 2015191892 A2	17-12-2015
WO 2008084237 A2	17-07-2008	CA 2674765 A1	17-07-2008
		EP 2114456 A2	11-11-2009
		ES 2537963 T3	16-06-2015
		JP 5541925 B2	09-07-2014
		JP 2010515713 A	13-05-2010
		US 2010028372 A1	04-02-2010
		US 2015071879 A1	12-03-2015
		US 2017202954 A1	20-07-2017
		US 2020147206 A1	14-05-2020
		WO 2008084237 A2	17-07-2008
WO 2006138181 A2	28-12-2006	AU 2006259664 A1	28-12-2006
		BR PI0611901 A2	28-08-2012
		CA 2610839 A1	28-12-2006
		CN 101217979 A	09-07-2008
		EA 200800050 A1	28-04-2008
		EP 1909831 A2	16-04-2008
		EP 3351269 A1	25-07-2018
		EP 3673919 A1	01-07-2020
		ES 2776657 T3	31-07-2020
		HK 1256288 A1	20-09-2019
		JP 5856555 B2	10-02-2016
		JP 6293103 B2	14-03-2018
		JP 2008543839 A	04-12-2008
		JP 2013047261 A	07-03-2013
		JP 2016053061 A	14-04-2016
		JP 2018048196 A	29-03-2018
		JP 2020183421 A	12-11-2020
		KR 20080031684 A	10-04-2008
		SG 162788 A1	29-07-2010
		US 2008311078 A1	18-12-2008
		US 2012028877 A1	02-02-2012
		US 2013273066 A1	17-10-2013
		US 2013273067 A1	17-10-2013
		US 2016319011 A1	03-11-2016
		US 2016339102 A1	24-11-2016
		US 2016362484 A1	15-12-2016
		US 2016362485 A1	15-12-2016
		US 2016362486 A1	15-12-2016
		US 2016367665 A1	22-12-2016
		US 2016367666 A1	22-12-2016
		US 2017368170 A1	28-12-2017
		WO 2006138181 A2	28-12-2006

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2022/016864

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		ZA 200800338 B	30-06-2010
